uu.seUppsala University Publications
Change search
Refine search result
1234567 51 - 100 of 411
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 51.
    Björksved, Margitha
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Department of Orthodontics, Public Dental Health Service, Eskilstuna, Sweden;Department of Orthodontics, Postgraduate Dental Education Center, Örebro, Sweden.
    Arnrup, Kristina
    Dental Research Department, Public Dental Service, Region Örebro County, Örebro, Sweden;School of Health Sciences, Örebro University, Örebro, Sweden.
    Lindsten, Rune
    Department of Orthodontics, The Institute for Postgraduate Dental Education, Jönköping, Sweden.
    Magnusson, Anders
    Department of Orthodontics, The Institute for Postgraduate Dental Education, Jönköping, Sweden.
    Sundell, Anna Lena
    Department of Paediatric Dentistry, The Institute for Postgraduate Dental Education, Jönköping, Sweden.
    Gustafsson, Annika
    Department of Paediatric Dentistry, The Institute for Postgraduate Dental Education, Jönköping, Sweden.
    Bazargani, Farhan
    Department of Orthodontics, Postgraduate Dental Education Center, Örebro, Sweden;School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Closed vs open surgical exposure of palatally displaced canines: surgery time, postoperative complications, and patients' perceptions2018In: European Journal of Orthodontics, ISSN 0141-5387, E-ISSN 1460-2210, Vol. 40, no 6, p. 626-635Article in journal (Refereed)
    Abstract [en]

    Background: Closed and open surgical techniques are two different main approaches to surgical exposure of palatally displaced canines (PDCs). Because there is insufficient evidence to support one technique over the other, there is a need for randomized controlled trials.

    Objectives: To compare surgery time, complications and patients' perceptions between closed and open surgical techniques in PDCs.

    Trial design: The trial was a multicentre, randomized, controlled trial with two parallel groups randomly allocated in a 1:1 ratio.

    Material and methods: Study participants were 119 consecutive patients from 3 orthodontic centres, with PDCs planned for surgical exposure, randomly allocated according to a computer-generated randomization list, using concealed allocation. Full-thickness mucoperiosteal flap was raised, and bone covering the canine was removed in both interventions. In closed exposure, an attachment with a chain was bonded to the canine and the flap was sutured back with the chain penetrating the mucosa. In open exposure, a window of tissue around the tooth was removed and glass ionomer cement placed on the canine crown, to prevent gingival overgrowth during spontaneous eruption. Patient perceptions were assessed with two questionnaires, for the evening on the day of operation and 7 days post-surgery.

    Blinding: It was not possible to blind either patients or care providers to the interventions. The outcome assessors were blinded and were unaware of patients' intervention group.

    Results: Seventy-five girls and 44 boys, mean age 13.4 years (SD 1.46) participated in the study and got either of the interventions (closed exposure, n = 60; open exposure, n = 59). Surgery time did not differ significantly between the interventions. Complications though were more severe in bilateral cases and the patients experienced more pain and impairment in the open group.

    Conclusion: There were no statistically significant differences regarding surgery time between the groups. Postoperative complications were similar between the groups in unilateral PDCs, but more common in the open group in bilateral cases. More patients in the open group experienced pain and impairment compared to the closed group.

    Trial registration: Trial registration: ClinicalTrials.gov, ID: NCT02186548 and Researchweb.org, ID: 127201.

  • 52. Bosnic-Anticevich, S
    et al.
    Costa, E
    Menditto, E
    Lourenço, O
    Novellino, E
    Bialek, S
    Briedis, V
    Buonaiuto, R
    Chrystyn, H
    Cvetkovski, B
    Capua, S Di
    Kritikos, V
    Mair, A
    Orlando, V
    Paulino, E
    Salimäki, J
    Söderlund, R
    Tan, R
    Williams, D M
    Wroczynski, P
    Agache, I
    Ansotegui, I J
    Anto, J M
    Bedbrook, A
    Bachert, C
    Bewick, M
    Bindslev-Jensen, C
    Brozek, J
    Canonica, G W
    Cardona, V
    Carr, W
    Casale, T
    Chavannes, N H
    Correia de Sousa, J
    Cruz, A A
    Czarlewski, W
    De Carlo, G
    Demoly, P
    Devillier, P
    Dykewicz, M S
    Gaga, M
    El-Gamal, Y
    Fonseca, J
    Fokkens, W J
    Guzmán, M A
    Haahtela, T
    Hellings, P W
    Illario, M
    Ivancevich, J C
    Just, J
    Kaidashev, I
    Khaitov, M
    Khaltaev, N
    Keil, T
    Klimek, L
    Kowalski, M L
    Kuna, P
    Kvedariene, V
    Larenas-Linnemann, D
    Laune, D
    Le, L T T
    Carlsen, K C Lodrup
    Mahboub, B
    Maier, D
    Malva, J
    Manning, P
    Morais-Almeida, M
    Mösges, R
    Mullol, J
    Münter, L
    Murray, R
    Naclerio, R
    Namazova-Baranova, L
    Nekam, K
    Nyembue, T D
    Okubo, K
    O'Hehir, R E
    Ohta, K
    Okamoto, Y
    Onorato, G L
    Palkonen, S
    Panzner, P
    Papadopoulos, N G
    Park, H S
    Pawankar, R
    Pfaar, O
    Phillips, J
    Plavec, D
    Popov, T A
    Potter, P
    Prokopakis, E P
    Roller-Wirnsberger, R E
    Rottem, M
    Ryan, D
    Samolinski, B
    Sanchez-Borges, M
    Schunemann, H J
    Sheikh, A
    Sisul, J C
    Somekh, D
    Stellato, C
    To, T
    Todo-Bom, A
    Tomazic, P V
    Toppila-Salmi, S
    Valero, A
    Valiulis, A
    Valovirta, E
    Ventura, M T
    Wagenmann, M
    Wallace, D
    Waserman, S
    Wickman, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Yiallouros, P K
    Yorgancioglu, A
    Yusuf, O M
    Zar, H J
    Zernotti, M E
    Zhang, L
    Zidarn, M
    Zuberbier, T
    Bousquet, J
    ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy"2019In: Allergy. European Journal of Allergy and Clinical Immunology, ISSN 0105-4538, E-ISSN 1398-9995, Vol. 74, no 7, p. 1219-1236Article, review/survey (Refereed)
    Abstract [en]

    Pharmacists are trusted health professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact of allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The ARIA-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses) and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of AR. However, the ARIA-pharmacy ICP should be adapted to local health care environments/situations as regional (national) differences exist in pharmacy care.

  • 53. Bousquet, J
    et al.
    Arnavielhe, S
    Bedbrook, A
    Bewick, M
    Laune, D
    Mathieu-Dupas, E
    Murray, R
    Onorato, G L
    Pépin, J L
    Picard, R
    Portejoie, F
    Costa, E
    Fonseca, J
    Lourenço, O
    Morais-Almeida, M
    Todo-Bom, A
    Cruz, A A
    da Silva, J
    Serpa, F S
    Illario, M
    Menditto, E
    Cecchi, L
    Monti, R
    Napoli, L
    Ventura, M T
    De Feo, G
    Larenas-Linnemann, D
    Fuentes Perez, M
    Huerta Villabolos, Y R
    Rivero-Yeverino, D
    Rodriguez-Zagal, E
    Amat, F
    Annesi-Maesano, I
    Bosse, I
    Demoly, P
    Devillier, P
    Fontaine, J F
    Just, J
    Kuna, T P
    Samolinski, B
    Valiulis, A
    Emuzyte, R
    Kvedariene, V
    Ryan, D
    Sheikh, A
    Schmidt-Grendelmeier, P
    Klimek, L
    Pfaar, O
    Bergmann, K C
    Mösges, R
    Zuberbier, T
    Roller-Wirnsberger, R E
    Tomazic, P
    Fokkens, W J
    Chavannes, N H
    Reitsma, S
    Anto, J M
    Cardona, V
    Dedeu, T
    Mullol, J
    Haahtela, T
    Salimäki, J
    Toppila-Salmi, S
    Valovirta, E
    Gemicioğlu, B
    Yorgancioglu, A
    Papadopoulos, N
    Prokopakis, E P
    Bosnic-Anticevich, S
    O'Hehir, R
    Ivancevich, J C
    Neffen, H
    Zernotti, E
    Kull, I
    Melen, E
    Wickman, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Bachert, C
    Hellings, P
    Palkonen, S
    Bindslev-Jensen, C
    Eller, E
    Waserman, S
    Sova, M
    De Vries, G
    van Eerd, M
    Agache, I
    Casale, T
    Dykewickz, M
    Naclerio, R N
    Okamoto, Y
    Wallace, D V
    MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence.2018In: Clinical and Translational Allergy, ISSN 2045-7022, E-ISSN 2045-7022, Vol. 8, article id 45Article in journal (Refereed)
    Abstract [en]

    mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary.

  • 54.
    Bousquet, J.
    et al.
    MACVIA France, Malad Chron VIeillissement Actif France European, Montpellier, France;INSERM, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, U1168, Villejuif, France;Univ Versailles St Quentin En Yvelines, UMR S 1168, Montigny Le Bretonneux, France;Euforea, Brussels, Belgium;Charite, Berlin, Germany.
    Devillier, P.
    Suresnes Univ Versailles St Quentin, Lab Pharmacol Resp, UPRES EA220, Pole Malad Resp,Hop Foch, Suresnes, France.
    Anto, J. M.
    Ctr Res Environm Epidemiol CREAL, ISGloBAL, Barcelona, Spain;IMIM Hosp Mar Res Inst, Barcelona, Spain;CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain;Univ Pompeu Fabra UPF, Barcelona, Spain.
    Bewick, M.
    IQ4U Consultants Ltd, London, England.
    Haahtela, T.
    Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland.
    Arnavielhe, S.
    Kyomed, Montpellier, France.
    Bedbrook, A.
    MACVIA France, Malad Chron VIeillissement Actif France European, Montpellier, France.
    Murray, R.
    MedScript Ltd, Dundalk, Ireland.
    van Eerd, M.
    Peercode DV, Gerdermalsen, Netherlands.
    Fonseca, J. A.
    Univ Porto, Fac Med, MEDIDA Lda, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal.
    Morais Almeida, M.
    Hosp CUF Descobertas, Allergy & Clin Immunol Dept, Lisbon, Portugal.
    Todo Bom, A.
    Univ Coimbra, Fac Med, Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal.
    Menditto, E.
    Univ Naples Federico II, Ctr Pharmacoecon, CIRFF, Naples, Italy.
    Passalacqua, G.
    Univ Genoa, Osped Policlin San Martino, Allergy & Resp Dis, Genoa, Italy.
    Stellato, C.
    Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Salerno, Italy.
    Triggiani, M.
    Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Salerno, Italy.
    Ventura, M. T.
    Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Bari, Italy.
    Vezzani, G.
    AUSL Reggio Emilia, Arcispedale SMaria Nuova IRCCS, Dept Med Specialties, Pulm Unit, Reggio Emilia, Italy.
    Annesi-Maesano, I.
    UPMC Sorbonne Univ, Med Sch St Antoine, Dept Inst Pierre Louis Epidemiol & Publ Hlth, INSERM,Epidemiol Allerg & Resp Dis, Paris, France.
    Bourret, R.
    Ctr Hosp, Valenciennes, France.
    Bosse, I.
    Allergist, La Rochelle, France.
    Caimmi, D.
    UPMC Paris 06, Sorbonne Univ, CHRU Montpellier, UMR S 1136,IPLESP,Equipe EPAR, Paris, France.
    Cartier, C.
    ASA Adv Solut Accelerator, Clapiers, France.
    Demoly, P.
    UPMC Paris 06, Sorbonne Univ, CHRU Montpellier, UMR S 1136,IPLESP,Equipe EPAR, Paris, France.
    Just, J.
    Hop Enfants Armand Trousseau, AP HP, Ctr Asthme & Allergies, Allergol Dept, Paris, France;UPMC Univ Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,Inst Pierre Louis Epidemiol & Sante Pu, Paris, France.
    Portejoie, F.
    MACVIA France, Malad Chron VIeillissement Actif France European, Montpellier, France.
    Siroux, V.
    Univ Joseph Fourier, Univ Grenoble Alpes, Team Environm Epidemiol Appl Reprod & Resp Hlth, INSERM,IAB,U1209, Grenoble, France.
    Viart, F.
    ASA Adv Solut Accelerator, Clapiers, France.
    Bergmann, K. C.
    Charite Univ Med Berlin, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany;Global Allergy & Asthma European Network GA2LEN, Berlin, Germany.
    Keil, T.
    Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany;Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany.
    Klimek, L.
    Ctr Rhinol & Allergol, Wiesbaden, Germany;Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany.
    Moesges, R.
    CRI Clin Res Int Ltd, Hamburg, Germany.
    Pfaar, O.
    Ctr Rhinol & Allergol, Wiesbaden, Germany;Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany.
    Shamai, S.
    CRI Clin Res Int Ltd, Hamburg, Germany;Univ Cologne, Inst Med Stat & Computat Biol, Fac Med, Cologne, Germany.
    Zuberbier, T.
    Charite Univ Med Berlin, Comprehens Allergy Ctr, Dept Dermatol & Allergy, Berlin, Germany;Global Allergy & Asthma European Network GA2LEN, Berlin, Germany.
    Mullol, J.
    Univ Barcelona, Hosp Clin, ENT Dept, Rhinol Unit, Barcelona, Spain;Univ Barcelona, Hosp Clin, ENT Dept, Smell Clin, Barcelona, Spain;Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain.
    Valero, A.
    Univ Barcelona, Hosp Clin, ENT Dept, Rhinol Unit, Barcelona, Spain;Univ Barcelona, Hosp Clin, ENT Dept, Smell Clin, Barcelona, Spain;Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain.
    Spranger, O.
    Global Allergy & Asthma Platform GAAPP, Vienna, Austria.
    Tomazic, P. V.
    Med Univ Graz, Dept ENT, Graz, Austria.
    Kowalski, M. L.
    Med Univ Lodz, HARC, Dept Immunol Rheumatol & Allergy, Lodz, Poland.
    Kuna, P.
    Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland.
    Kupczyk, M.
    Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland.
    Raciborski, F.
    Med Univ Warsaw, Dept Prevent Envinronmental Hazards & Allergol, Warsaw, Poland.
    Samolinski, B.
    Med Univ Warsaw, Dept Prevent Envinronmental Hazards & Allergol, Warsaw, Poland.
    Toppila-Salmi, S. K.
    Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland.
    Valovirta, E.
    Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland;Terveystalo Allergy Clin, Turku, Finland.
    Cruz, A. A.
    Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil;GARD Execut Comm, Salvador, BA, Brazil.
    Sarquis-Serpa, F.
    Escola Super Ciencias Santa Casa de Misericordia, Asthma Reference Ctr, Vitoria, ES, Brazil.
    da Silva, J.
    Fed Univ Santa Catarina HU UFSC, Hosp Univ Polydoro Ernani de Sao Thiago, Nucleo Alergia, Florianopolis, SC, Brazil.
    Stelmach, R.
    Univ Sao Paulo, Heart Inst InCor, Div Pulm, Hosp Clin,Fac Med, Sao Paulo, Brazil.
    Larenas-Linnemann, D.
    Hosp Med Sur, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico.
    Rodriguez Gonzalez, M.
    Hosp Angeles Pedregal, Pediat Allergy & Clin Immunol, Mexico City, DF, Mexico.
    Burguete Cabanas, M. T.
    Ctr Med Zambrano Hell, Monterrey, Mexico.
    Kvedariene, V.
    Vilnius Univ, Clin Infecious Chest Dis Dermatol & Allergol, Dept Pathol Forens Med & Pharmacol, Fac Med,Inst Biomed Sci, Vilnius, Lithuania;Inst Clin Med, Clin Infecious Chest Dis Dermatol & Allergol, Vilnius, Lithuania.
    Valiulis, A.
    Vilnius Univ, Inst Clin Med, Inst Hlth Sci, Dept Publ Hlth,Clin Childrens Dis, Vilnius, Lithuania;European Acad Paediat EAP UEMS SP, Brussels, Belgium.
    Chavannes, N. H.
    Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands.
    Fokkens, W. J.
    Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands.
    Ryan, D.
    Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland.
    Sheikh, A.
    Univ Edinburgh, Inst Populat Hlth Sci & Informat, Med Informat Ctr, Asthma UK Ctr Appl Res, Edinburgh, Midlothian, Scotland.
    Bachert, C.
    Ghent Univ Hosp, Upper Airways Res Lab, ENT Dept, Ghent, Belgium.
    Hellings, P. W.
    Euforea, Brussels, Belgium;Univ Hosp Leuven, Dept Otorhinolaryngol, Leuven, Belgium;Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands.
    VandenPlas, O.
    Catholic Univ Louvain, Dept Chest Med, Ctr Hosp Univ UCL Namur, Yvoir, Belgium.
    Ballardini, N.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Kull, I.
    Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland;Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden.
    Melen, E.
    Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden;Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Westman, M.
    Karolinska Inst, Immunol & Allergy Unit, Dept Med Solna, Stockholm, Sweden;Karolinska Univ Hosp, Dept ENT Dis, Stockholm, Sweden.
    Wickman, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Bindslev-Jensen, C.
    Odense Univ Hosp, ORCA, Dept Dermatol, Odense, Denmark;Odense Univ Hosp, ORCA, Allergy Ctr, Odense, Denmark.
    Eller, E.
    Odense Univ Hosp, ORCA, Dept Dermatol, Odense, Denmark;Odense Univ Hosp, ORCA, Allergy Ctr, Odense, Denmark.
    Bosnic-Anticevich, S.
    Univ Sydney, Woolcock Inst Med Res, Sydney Local Hlth Dist, Glebe, NSW, Australia.
    O'Hehir, R. E.
    Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia;Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia;Monash Univ, Dept Immunol, Melbourne, Vic, Australia.
    Agache, I.
    Transylvania Univ, Brasov, Romania.
    Bieber, T.
    Rheinische Friedrich Wilhelms Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany.
    Casale, T.
    Univ S Florida, Div Allergy Immunol, Tampa, FL USA.
    Gemicioglu, B.
    Istanbul Univ, Cerrahpasa Fac Med, Dept Pulm Dis, Istanbul, Turkey.
    Ivancevich, J. C.
    Clin Santa Isabel, Serv Alergia & Immunol, Buenos Aires, DF, Argentina.
    De Vries, G.
    Peercode DV, Gerdermalsen, Netherlands.
    Sorensen, M.
    Univ Hosp North Norway, Dept Paediat & Adolescent Med, Tromso, Norway;UiT, Paediat Res Grp, Dept Clin Med, Tromso, Norway.
    Yorgancioglu, A.
    Celal Bayar Univ, Dept Pulmonol, Manisa, Turkey;GARD Execut Comm, Manisa, Turkey.
    Laune, D.
    Kyomed, Montpellier, France.
    Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study2018In: Allergy. European Journal of Allergy and Clinical Immunology, ISSN 0105-4538, E-ISSN 1398-9995, Vol. 73, no 8, p. 1622-1631Article, review/survey (Refereed)
    Abstract [en]

    BackgroundMultimorbidity in allergic airway diseases is well known, but no data exist about the daily dynamics of symptoms and their impact on work. To better understand this, we aimed to assess the presence and control of daily allergic multimorbidity (asthma, conjunctivitis, rhinitis) and its impact on work productivity using a mobile technology, the Allergy Diary. MethodsWe undertook a 1-year prospective observational study in which 4 210 users and 32585days were monitored in 19 countries. Five visual analogue scales (VAS) assessed the daily burden of the disease (i.e., global evaluation, nose, eyes, asthma and work). Visual analogue scale levels <20/100 were categorized as "Low" burden and VAS levels 50/100 as "High" burden. ResultsVisual analogue scales global measured levels assessing the global control of the allergic disease were significantly associated with allergic multimorbidity. Eight hypothesis-driven patterns were defined based on "Low" and "High" VAS levels. There were <0.2% days of Rhinitis Low and Asthma High or Conjunctivitis High patterns. There were 5.9% days with a Rhinitis HighAsthma Low pattern. There were 1.7% days with a Rhinitis HighAsthma HighConjunctivitis Lowpattern. A novel Rhinitis HighAsthma HighConjunctivitis High pattern was identified in 2.9% days and had the greatest impact on uncontrolled VAS global measured and impaired work productivity. Work productivity was significantly correlated with VAS global measured levels. ConclusionsIn a novel approach examining daily symptoms with mobile technology, we found considerable intra-individual variability of allergic multimorbidity including a previously unrecognized extreme pattern of uncontrolled multimorbidity.

  • 55.
    Bousquet, J. Jean
    et al.
    CHU, Fondat Partenariale FMC VIA LR, MACVIA France, F-34295 Montpellier 5, France;Villejuif Univ Versailles St Quentin En Yvelines, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, INSERM U 1168, UMR S 1168, Montigny Le Bretonneux, France;European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium;Charite Univ Med Berlin, Berlin, Germany;Free Univ Berlin, Berlin, Germany;Humboldt Uniersitat Berlin, Berlin, Germany.
    Schunemann, Holger J.
    McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
    Togias, Alkis
    NIAID, DAIT, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
    Erhola, Marina
    Natl Inst Hlth & Welf, Helsinki, Finland.
    Hellings, Peter W.
    European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium;Univ Hosp Leuven, Dept Otorhinolaryngol, Louvain, Belgium;Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands.
    Zuberbier, Torsten
    Charite Univ Med Berlin, Berlin, Germany;Free Univ Berlin, Berlin, Germany;Humboldt Uniersitat Berlin, Berlin, Germany;Berlin Inst Hlth, Comprehens Allergy Ctr, GA2LEN, Dept Dermatol & Allergy, Berlin, Germany.
    Agache, Ioana
    Transylvania Univ, Fac Med, Brasov, Romania.
    Ansotegui, Ignacio J.
    Hosp Quironsalud Bizkaia, Dept Allergy & Immunol, Erandio, Spain.
    Anto, Josep M.
    Ctr Res Environm Epidemiol CREAL, ISGlobAL, Barcelona, Spain;Hosp del Mar, Res Inst, IMIM, Barcelona, Spain;CIBERESP, Barcelona, Spain;UPF, Barcelona, Spain.
    Bachert, Claus
    Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium.
    Becker, Sven
    Johannes Gutenberg Univ Mainz, Dept Otolaryngol Head & Neck Surg, Mainz, Germany.
    Bedolla-Barajas, Martin
    Hosp Civil Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico.
    Bewick, Michael
    iQ4U Consultants Ltd, London, England.
    Bosnic-Anticevich, Sinthia
    Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia;Woolcock Emphysema Ctr, Sydney, NSW, Australia;Sydney Local Hlth Dist, Glebe, NSW, Australia.
    Bosse, Isabelle
    Boulet, Louis P.
    Laval Univ, Quebec Heart & Lung Inst, Quebec City, PQ, Canada.
    Bourrez, Jean Marc
    EFT Hlth France, Paris, France.
    Brusselle, Guy
    Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium.
    Chavannes, Niels
    Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands.
    Costa, Elisio
    Univ Porto, Porto4Ageing, Fac Pharm, UCIBIO,REQUINTE, Porto, Portugal;Univ Porto, Porto4Ageing, Competence Ctr Act & Hlth Ageing, Porto, Portugal.
    Cruz, Alvaro A.
    Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil;WHO GARD Planning Grp, Salvador, BA, Brazil.
    Czarlewski, Wienczyslawa
    Med Consulting Czarlewski, Levallois Perret, France.
    Fokkens, Wytske J.
    European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium;Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, AMC, Amsterdam, Netherlands.
    Fonseca, Joao A.
    Univ Porto, Fac Med, Ctr Res Hlth Technol & Informat Syst, CINITESIS, Porto, Portugal;Medida Lda, Porto, Portugal.
    Gaga, Mina
    Athens Chest Hosp, Resp Med Dept 7, Athens, Greece;Athens Chest Hosp, Asthma Ctr, Athens, Greece.
    Haahtela, Tari
    Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland;Univ Helsinki, Helsinki, Finland.
    Illario, Maddalena
    Medida Lda, Porto, Portugal;Campania Reg, Div Hlth Innovat, Naples, Italy;Federico II Univ Hosp Naples, R&D, Naples, Italy;Federico II Univ Hosp Naples, DISMET, Naples, Italy.
    Klimek, Ludger
    Ctr Rhinol & Allergol, Wiesbaden, Germany.
    Kuna, Piotr
    Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland.
    Kvedariene, Violeta
    Vilnius Univ, Fac Med, Vilnius, Lithuania.
    Le, L. T. T.
    Univ Med & Pharm, Hochiminh City, Vietnam.
    Larenas-Linnemann, Desiree
    Med Sur Clin Fdn & Hosp, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico.
    Laune, Daniel
    KYomed INNOV, Montpellier, France.
    Lourenco, Olga M.
    Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal;Univ Beira Interior, Hlth Sci Res Ctr, CICS UBI, Covilha, Portugal.
    Menditto, Enrica
    Univ Naples Federico II, CIRFF, Naples, Italy.
    Mullo, Joaquin
    Hosp Clin Barcelona, ENT Dept, Rhinol Unit, Barcelona, Spain;Hosp Clin Barcelona, ENT Dept, Smell Clin, Barcelona, Spain;Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain.
    Okamoto, Yashitaka
    Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan.
    Papadopoulos, Nikos
    Univ Manchester, Royal Manchester Childrens Hosp, Div Infect Immun & Resp Med, Manchester, Lancs, England;Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Pediat Clin 2, Allergy Dept, Athens, Greece.
    Pham-Thi, Nhan
    Picard, Robert
    Minist Econ Ind & Numer, Conseil Gen Econ, Paris, France.
    Pinnock, Hilary
    Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
    Roche, Nicolas
    Hop Univ Paris, Ctr Hop Cochin, Pneumol & Soins Intensifs Resp, Paris, France.
    Roller-Wirnsberger, Regina E.
    Med Univ Graz, Dept Internal Med, Graz, Austria.
    Rolland, Christine
    Assoc Asthme & Allergie, Paris, France.
    Samolinski, Boleslaw
    Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland.
    Sheikh, Aziz
    Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
    Toppila-Salmi, Sanna
    Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland;Univ Helsinki, Helsinki, Finland.
    Tsiligianni, Ioanna
    Univ Crete, Fac Med, Dept Social Med, Hlth Planning Unit, Iraklion, Greece;IPCRG, Aberdeen, Scotland.
    Valiulis, Arunas
    Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania;Vilnius Univ, Fac Med, Inst Hlth Sci, Vilnius, Lithuania.
    Valovirta, Erkka
    Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland;Terveystalo Allergy Clin, Turku, Finland.
    Vasankari, Tuula
    Finnish Lung Assoc, FILHA, Helsinki, Finland.
    Ventura, Maria-Teresa
    Walker, Samantha
    Univ Bari, Med Sch, Unit Geriatr Immunoallergol, Bari, Italy.
    Williams, Sian
    Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland;Terveystalo Allergy Clin, Turku, Finland.
    Akdis, Cezmi A.
    Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.
    Annesi-Maesano, Isabella
    INSERM, Dept Inst Pierre Louis Epidemiol & Publ Hlth, Epidemiol Allerg & Resp Dis, Paris, France;Sorbonne Univ, Med Sch St Antoine, Paris, France.
    Arnavielhe, Sylvie
    KYomed INNOV, Montpellier, France.
    Basagana, Xavier
    Ctr Res Environm Epidemiol CREAL, ISGlobAL, Barcelona, Spain;Hosp del Mar, Res Inst, IMIM, Barcelona, Spain;CIBERESP, Barcelona, Spain;UPF, Barcelona, Spain.
    Bateman, Eric
    Univ Cape Town, Dept Med, Cape Town, South Africa.
    Bedbrook, Anna
    CHU, Fondat Partenariale FMC VIA LR, MACVIA France, F-34295 Montpellier 5, France.
    Bennoor, K. S.
    Natl Inst Dis Chest & Hosp, Dept Resp Med, Dhaka, Bangladesh.
    Benveniste, Samuel
    Broca Hosp, Natl Ctr Expertise Cognit Stimulat CEN STIMCO, Paris, France.
    Bergmann, Karl C.
    Charite Univ Med Berlin, Berlin, Germany;Free Univ Berlin, Berlin, Germany;Humboldt Uniersitat Berlin, Berlin, Germany;Berlin Inst Hlth, Comprehens Allergy Ctr, GA2LEN, Dept Dermatol & Allergy, Berlin, Germany.
    Bia, Slawomir
    Warsaw Med Univ, Div Lab Med, Fac Pharm, Dept Biochem & Clin Chem, Warsaw, Poland.
    Billo, Nils
    Global Alliance Chron Resp Dis WHO GARD, Joensuu, Finland.
    Bindslev-Jensen, Carsten
    Odense Univ Hosp, Odense Res Ctr Anaphylaxis, Dept Dermatol, Odense, Denmark;Odense Univ Hosp, Odense Res Ctr Anaphylaxis, Allergy Ctr, Odense, Denmark;Termofischer Sci, Uppsala, Sweden.
    Bjermer, Leif
    Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden.
    Blain, Hubert
    Montpellier Univ Hosp, Dept Geriatr, Montpellier, France;Univ Montpellier, EA Euromov 2991, Montpellier, France.
    Bonini, Mateo
    Univ Cattolica Sacro Cuore, F Policlin Gemelli IRCCS, UOC Pneumol, Ist Med Interna, Rome, Italy;Royal Brompton Hosp, Natl Heart & Lung Inst, London, England;Imperial Coll, London, England.
    Bonniaud, Philippe
    CHU, Dijon, France.
    Bouchard, Jacques
    Lavals Univ, Clin Med, Quebec City, PQ, Canada;Hop Malbaie, Med Dept, Quebec City, PQ, Canada.
    Briedis, Vitalis
    Univ Hlth, Dept Clin Pharm Lithuanian, Kaunas, Lithuania.
    Brightling, Christofer E.
    Univ Hosp Leicester NHS Trust, Inst Lung Hlth, Resp Biomed Unit, Leicester, Leics, England;Univ Leicester, Dept Infect Immun & Inflammat, Leicester, Leics, England.
    Brozek, Jan
    McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
    Buhl, Roland
    Johannes Gutenberg Univ Mainz, Univ Med, Mainz, Germany.
    Buonaiuto, Roland
    Municipal Pharm, Sarno, Italy.
    Canonica, Giorgo W.
    Humanitas Univ, Humanitas Res Hosp, Personalized Med Clin Asthma & Allergy, Milan, Italy.
    Cardona, Victoria
    Hosp Valle De Hebron, Dept Internal Med, Allergy Sect, Barcelona, Spain;ARADyAL Res Network, Barcelona, Spain.
    Carriazo, Ana M.
    Reg Minist Hlth Andalusia, Seville, Spain.
    Carr, Warner
    Allergy & Asthma Associates Southern Calif, Mission Viejo, CA USA.
    Cartier, Christine
    Adv Solut Accelerator, Clapiers, France.
    Casale, Thomas
    Univ S Florida, Div Allergy Immunol, Tampa, FL USA.
    Cecchi, Lorenzo
    USL Toscana Ctr, SOS Allergol & Clin Immunol, Prato, Italy.
    Cepeda Sarabia, Alfonso M.
    Simon Bolivar Univ, Metropolitan Univ, Allergy & Immunol Lab, Barranquilla, Colombia;SLaai, Barranquilla, Colombia.
    Chkhartishvili, Eka
    Grigol Robakidze Univ, David Tvildiani Med Univ, AIETI Med Sch, Chachava Clin, Tbilisi, Georgia.
    Chu, Derek K.
    European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium.
    Cingi, Cemal
    Eskisehir Osmangazi Univ, Med Fac, ENT Dept, Eskisehir, Turkey.
    Colgan, Elaine
    Dept Hlth Social Serv & Publ Safety, Belfast, Antrim, North Ireland.
    de Sousa, Jaime Correia
    Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal;ICVS 3Bs, PT Govt Associate Lab, Braga, Portugal.
    Courbis, Anne Lise
    Ecole Mines, Ales, France.
    Custovic, Adnan
    Univ Manchester, Ctr Resp Med & Allergy, Inst Inflammat & Repair, Manchester, Lancs, England;Univ Hosp South Manchester, Manchester, Lancs, England.
    Cvetkosvki, Biljana
    Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia;Woolcock Emphysema Ctr, Sydney, NSW, Australia;Sydney Local Hlth Dist, Glebe, NSW, Australia.
    D'Amato, Gennaro
    High Specialty Hosp A Cardarelli, Dept Resp Dis, Div Resp & Allerg Dis, Naples, Italy.
    da Silva, Jane
    Univ Hosp Fed Univ Santa Catarina HU UFSQ, Allergy Serv, Florianopolis, SC, Brazil.
    Dantas, Carina
    Caritas Diocesana Coimbra, Coimbra, Portugal;Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal.
    Dokic, Dejand
    Univ Clin Pulmonol & Allergy, Med Fac Skopje, Skopje, Macedonia.
    Dauvilliers, Yves
    Hop Gui de Chauliac Montpellier, Sleep Unit, Dept Neurol, Inserm U1061, Montpellier, France.
    Dedeu, Antoni
    AQuAS, Barcelna, Spain;European Reg & Local Hlth Assoc, EUREGHA, Brussels, Belgium.
    De Feo, Giulia
    Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Salerno, Italy.
    Devillier, Philippe
    Univ Paris Saclay, Hop Foch, Pole Malad Voies Resp, UPRES EA220, Suresnes, France.
    Di Capua, Stefania
    Farmacie Golfi Grp, Massa Lubrense, Italy.
    Dykewickz, Marc
    St Louis Univ, Sch Med, Sect Allergy & Immunol, St Louis, MO USA.
    Dubakiene, Ruta
    Vilnius Univ, Clin Infect Chest Dis Dermatol & Allergol, Vilnius, Lithuania.
    Ebisawa, Motohiro
    Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan.
    El-Gamal, Yaya
    Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt.
    Eller, Esben
    Odense Univ Hosp, Odense Res Ctr Anaphylaxis, Dept Dermatol, Odense, Denmark;Odense Univ Hosp, Odense Res Ctr Anaphylaxis, Allergy Ctr, Odense, Denmark;Termofischer Sci, Uppsala, Sweden.
    Emuzyte, Regina
    Vilnius Univ, Fac Med, Clin Childrens Dis, Vilnius, Lithuania.
    Farrell, John
    ICVS 3Bs, PT Govt Associate Lab, Braga, Portugal.
    Fink-Wagner, Antjie
    Global Allergy & Asthma Platform GAAPP, Vienna, Austria.
    Fiocchi, Alessandro
    Bambino Gesu Childrens Res Hosp Holy See, Dept Pediat Med, Div Allergy, Rome, Italy.
    Fontaine, Jean F.
    Gemicioglu, Bilun
    Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pulm Dis, Istanbul, Turkey.
    Schmid-Grendelmeir, Peter
    Univ Hosp Zurich, Dept Dermatol, Allergy Unit, Zurich, Switzerland.
    Gamkrelidze, Amiran
    Natl Ctr Dis Control & Publ Hlth Georgia, Tbilisi, Georgia.
    Garcia-Aymerich, Judith
    Ctr Res Environm Epidemiol CREAL, ISGlobAL, Barcelona, Spain.
    Gomez, Maximiliano
    Hosp San Bernardo Salta, Allergy & Asthma Unit, Salta, Argentina.
    Gonzalez Diaz, Sandra
    Univ Autonoma Nuevo Leon, San Nicolas De Los Garza, Mexico.
    Gotua, Maia
    Georgian Assoc Allergol & Clin Immunol, Ctr Allergy & Immunol, Tbilisi, Georgia.
    Guldemond, Nick A.
    Erasmus Univ, Inst Hlth Policy & Management iBMG, Rotterdam, Netherlands.
    Guzman, Maria-Antonieta
    Univ Chile, Clin Hosp, Immunol & Allergy Div, Santiago, Chile.
    Hajjam, Jawad
    Conseil Reg Pays Loire, Ctr Expertise Partenariat Europeen Innovat Vieill, Gerontopole Auton Longevite Pays Loire, Centich Ctr Expertise Natl Technol Informat & Com, Nantes, France.
    Hourihane, John O'B
    Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland.
    Humbert, Marc
    Univ Paris Sud, Le Kremlin Bicetre, France;Hop Bicetre, Serv Pneumol, Inserm UMR 5999, Le Kremlin Bicetre, France.
    Iaccarino, Guido
    Univ Salerno, Dept Med & Surg, Baronissi, Italy.
    Ierodiakonou, Despo
    Univ Crete, Fac Med, Dept Social Med, Hlth Planning Unit, Iraklion, Greece;Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland;Terveystalo Allergy Clin, Turku, Finland.
    Ivancevich, Juan C.
    Clin Santa Isabel, Serv Alergia & Immunol, Buenos Aires, DF, Argentina.
    Joos, Guy
    Laval Univ, Quebec Heart & Lung Inst, Quebec City, PQ, Canada.
    Jung, Ki-Suck
    Hallym Univ, Coll Med, Sacred Heart Hosp, Anyang, Gyeonggi Do, South Korea.
    Jutel, Marek
    Wroclaw Med Univ, Dept Clin Immunol, Wroclaw, Poland.
    Kaidashev, Igor
    Ukrainian Med Stomatol Acad, Poltava, Ukraine.
    Kalayci, Omer
    Hacettepe Univ, Pediat Allergy & Asthma Unit, Sch Med, Ankara, Turkey.
    Kardas, Przemyslaw
    Med Univ Lodz, Dept Family Med 1, Lodz, Poland.
    Keil, Thomas
    Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany;Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany.
    Khaitov, Mussa
    Fed Med Biol Agcy, Natl Res Ctr, Inst Immunol, Lab Mol Immunol, Moscow, Russia.
    Khaltaev, Nikolai
    GARD Chairman, Geneva, Switzerland.
    Kleine-Tebbe, Jorg
    Allergy & Asthma Ctr Westend, Berlin, Germany.
    Kowalski, Marek L.
    Med Univ Lodz, Hlth Ageing Res Ctr, Dept Immunol & Allergy, Lodz, Poland.
    Kritikos, Vicky
    Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia;Woolcock Emphysema Ctr, Sydney, NSW, Australia;Sydney Local Hlth Dist, Glebe, NSW, Australia.
    Kull, Inger
    Karolinska Inst, Soder Sjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden;Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden.
    Leonardini, Lisa
    Mattone Int Program, Bologna, Veneto Region, Italy.
    Lieberman, Philip
    Univ Tennessee, Coll Med, Dept Internal Med, Div Allergy, Germantown, TN USA;Univ Tennessee, Coll Med, Dept Internal Med, Div Immunol, Germantown, TN USA;Univ Tennessee, Coll Med, Dept Pediat, Div Allergy, Germantown, TN USA;Univ Tennessee, Coll Med, Dept Pediat, Div Immunol, Germantown, TN USA.
    Lipworth, Brian
    Univ Dundee, Ninewells Hosp, Med Res Inst, Scottish Ctr Resp Res Cardiovasc & Diabet Med, Dundee, Scotland.
    Carlsen, Karin C. Lodrup
    Oslo Univ Hosp, Dept Paediat, Oslo, Norway;Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway.
    Loureiro, Claudia C.
    Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal;Univ Coimbra, Fac Med, Coimbra, Portugal.
    Louis, Renaud
    CHU Sart Tilman, Dept Pulm Med, Liege, Belgium;GIGA I3 Res Grp, Liege, Belgium.
    Mair, Alpana
    Scottish Govt, DG Hlth & Social Care, Edinburgh, Midlothian, Scotland.
    Marien, Gert
    European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium.
    Mahboub, Bassam
    Rashid Hosp, Dept Pulm Med, Dubai, U Arab Emirates.
    Malva, Joao
    Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal;Univ Coimbra, Fac Med, Coimbra Inst Clin & Biomed Res iCBR, Coimbra, Portugal.
    Manning, Patrick
    Bon Secours Hosp, Dept Med RCSI, Dublin, Ireland.
    Keenoy, Esteban De Manuel
    Int Ctr Excellence Chronic Res Barakaldo, Kronikgune, Baracaldo, Bizkaia, Spain.
    Marshall, Gallen D.
    Univ Mississippi, Med Ctr, Div Clin Immunol & Allergy, Lab Behav Immunol Res, Jackson, MS 39216 USA.
    Masjedi, Mohamed R.
    Iranian Anti Tobacco Assoc, Tobacco Control Res Ctr, Tehran, Iran.
    Maspero, Jorge F.
    Argentine Assoc Allergy & Clin Immunol, Buenos Aires, DF, Argentina.
    Mathieu-Dupas, Eve
    KYomed INNOV, Montpellier, France.
    Matricardi, Poalo M.
    Charite Med Univ, Dept Pediat Pneumol & Immunol, AG Mol Allergol & Immunomodulat, Berlin, Germany.
    Melen, Eric
    Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden;Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Melo-Gomes, Elisabete
    Fac Med Lisbon, PNDR, Portuguese Natl Programme Resp Dis, Lisbon, Portugal.
    Meltzer, Eli O.
    Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA.
    Mercier, Jacques
    Univ Montpellier, CHRU, Dept Physiol, Res,PhyMedExp,INSERM U1046,CNRS,UMR 9214, Montpellier, France.
    Miculinic, Neven
    Croatian Pulm Soc, Zagreb, Croatia.
    Mihaltan, Florin
    Natl Inst Pneumol M Nasta, Bucharest, Romania.
    Milenkovic, Branislava
    Univ Belgrade, Fac Med, Clin Ctr Serbia, Serbian Assoc Asthma & COPD,Clin Pulm Dis, Belgrade, Serbia.
    Moda, Giuliana
    Reg Piemonte, Turin, Italy.
    Mogica-Martinezl, Maria-Dolores
    Mohammad, Yousser
    Tishreen Univ, Natl Ctr Res Chron Resp Dis, Sch Med, Latakia, Syria;Syrian Private Univ, Damascus, Syria.
    Montefort, Steve
    Univ Med, Fac Med & Surg, La Valette, Malta.
    Monti, Ricardo
    Univ Torino, Dept Med Sci, Allergy & Clin Immunol Unit, Turin, Italy;Mauriziano Hosp, Turin, Italy.
    Morais-Almeida, Mario
    CUF Descobertas Hosp, Allergy Ctr, Lisbon, Portugal.
    Moesges, Raft
    Univ Cologne, Med Fac, Inst Med Stat & Computat Biol, Cologne, Germany;CRI Clin Res Int Ltd, Hamburg, Germany.
    Munter, Lars
    Danish Commitee Hlth Educ, Copenhagen East, Denmark.
    Muraro, Antonella
    Padua Gen Univ Hosp, Food Allergy Referral Ctr Veneto Reg, Dept Women & Child Hlth, Padua, Italy.
    Murray, Ruth
    MedScript Ltd, Paraparomu, New Zealand;OPC, Cambridge, England.
    Naclerio, Robert
    Johns Hopkins Sch Med, Baltimore, MD USA.
    Napoli, Luigi
    Consortium Pharm & Serv COSAFER, Salerno, Italy.
    Namazova-Baranova, Leila
    Russian Acad Med Sci, Sci Ctr Childrens Hlth, Moscow, Russia.
    Neffen, Hugo
    Ctr Allergy Immunol & Resp Dis, Santa Fe, Argentina.
    Nekam, Kristoff
    Hosp Hosp Ler Bros Buda, Budapest, Hungary.
    Neou, Angelo
    Hautambulanz & Rothhaar Study Ctr, Berlin, Germany.
    Novellino, Enrico
    Univ Naples Federico II, Dept Pharm, Naples, Italy.
    Nyembue, Dieudonne
    Univ Hosp Kinshasa, ENT Dept, Kinshasa, DEM REP CONGO.
    O'Hehir, Robin
    Monash Univ, Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia;Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia.
    Ohta, Ken
    Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan.
    Okubo, Kimi
    Nippon Med Sch, Dept Otolaryngol, Tokyo, Japan.
    Onorato, Gabrielle
    CHU, Fondat Partenariale FMC VIA LR, MACVIA France, F-34295 Montpellier 5, France.
    Ouedraogo, Solange
    Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso.
    Pali-Schoell, Isabella
    Univ Vet Med, Messerli Res Inst, Dept Comparat Med, Vienna, Austria;Med Univ, Vienna, Austria.
    Palkonen, Susanna
    EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium.
    Panzner, Peter
    Charles Univ Prague, Fac Med, Dept Immunol & Allergol, Plzen, Czech Republic;Charles Univ Prague, Fac Hosp Pilsen, Plzen, Czech Republic.
    Park, Hae-Sim
    Ajou Univ, Dept Allergy & Clin Immunol, Sch Med, Suwon, South Korea.
    Pepin, Jean-Louis
    Univ Grenoble Alpes, Lab HP2, Grenoble, France;INSERM, U1042, Grenoble, France;CHU Grenoble, Grenoble, France.
    Pereira, Ana-Maria
    CUF Porto Hosp & Inst, Allergy Unit, Porto, Portugal;Univ Porto, Ctr Res Hlth Technol & Informat Syst, CINTESIS, Porto, Portugal.
    Pfaar, Oliver
    Philipps Univ Marburg, Univ Hosp Marburg, Sect Rhinol & Allergy, Dept Otorhinolaryngol Head & Neck Surg, Marburg, Germany.
    Paulino, Ema
    Farmacias Holon, Lisbon, Portugal.
    Phillips, Jim
    Ctr Empowering Patients & Communities, Faulkland, Somerset, England.
    Plavec, Davor
    Childrens Hosp Srebrnjak, Zagreb, Croatia;Univ JJ Strossmayer, Sch Med, Osijek, Croatia.
    Popov, Ted A.
    Univ Hosp Sv Ivan Rilski, Sofia, Bulgaria.
    Portejoie, Fabienne
    CHU, Fondat Partenariale FMC VIA LR, MACVIA France, F-34295 Montpellier 5, France.
    Price, David
    Univ Aberdeen, Acad Ctr Primary Care, Aberdeen, Scotland;Res Real Life, Cambridge, England.
    Prokopakis, Emmanuel P.
    Univ Crete, Dept Otorhinolaryngol, Sch Med, Iraklion, Greece.
    Pugin, Benoit
    European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium.
    Raciborski, Filip
    Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland.
    Rajabian-Soderlund, Rojin
    Karolinska Univ Hosp, Dept Nephrol & Endocrinol, Stockholm, Sweden.
    Reitsma, Sietze
    European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium;Amsterdam Univ Med Ctr, Dept Otorhinolaryngol, AMC, Amsterdam, Netherlands.
    Rodo, Xavier
    Ctr Res Environm Epidemiol CREAL, ISGlobAL, Barcelona, Spain.
    Romano, Antonino
    Univ Cattolica Sacro Cuore, Allergy Unit, Presidio Columbus, Rome, Italy;IRCCS Oasi Maria SS, Troina, Italy.
    Rosario, Nelson
    Univ Parana, Hosp Clin, Curitiba, Parana, Brazil.
    Rottem, Menahenm
    Emek Med Ctr, Div Allergy Asthma & Clin Immunol, Afula, Israel.
    Ryan, Dermot
    Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland.
    Salimaki, Johanna
    Assoc Finnish Pharmacists, Helsinki, Finland.
    Sanchez-Borges, Mario M.
    Ctr Medicodocente Trinidad & Clin El Avila, Allergy & Clin Immunol Dept, Caracas, Venezuela.
    Sisul, Juan-Carlos
    Soc Paraguaya Alergia Asma & Inmunol, Asuncion, Paraguay.
    Sole, Dirceu
    Univ Fed Sao Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, Sao Paulo, Brazil.
    Somekh, David
    EHEE, Dromahair, Ireland.
    Sooronbaev, Talant
    Euro Asian Resp Soc, Kyrgyzstan Natl Ctr Cardiol & Internal Med, Bishkek, Kyrgyzstan.
    Sova, Milan
    Univ Hosp Olomouc, Dept Resp Med, Olomouc, Czech Republic.
    Spranger, Otto
    Global Allergy & Asthma Platform GAAPP, Vienna, Austria.
    Stellato, Cristina
    Univ Salerno, Scuola Med Salernitana, Dept Med Surg & Dent, Salerno, Italy.
    Stelmach, Rafael
    Univ Sao Paulo, Fac Med, Hosp Clin, Pulm Div,Heart Inst InCor, Sao Paulo, Brazil.
    Ulrik, Charlotte Suppli
    Hvidovre Univ Hosp, Dept Resp Med, Copenhagen, Denmark;Univ Copenhagen, Copenhagen, Denmark.
    Thibaudon, Michel
    RNSA, Brussieu, France.
    To, Teresa
    Sidkkids Hosp, Toronto, ON, Canada;Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.
    Todo-Bom, Ana
    Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal;Univ Coimbra, Fac Med, Coimbra, Portugal.
    Tomazic, Peter, V
    Med Univ Graz, Dept ENT, Graz, Austria.
    Valero, Antonio A.
    Univ Barcelona, IDIBAPS, Pneumol & Allergy Dept, CIBERES, Barcelona, Spain;Univ Barcelona, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain.
    Valenta, Rudolph
    Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria;NRC Inst Immunol FMBA Russia, Moscow, Russia;Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Lab Immunopathol, Moscow, Russia.
    Valentin-Rostan, Marylin
    van der Kleij, Rianne
    Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands;Univ Med Ctr, Dept Obstet & Gynaecol, Erasmus MC, Rotterdam, Netherlands.
    Vandenplas, Olivier
    Catholic Univ Louvain, Ctr Hosp Univ UCL Namur, Dept Chest Med, Yvoir, Belgium.
    Vezzani, Giorgio
    AUSL Reggio Emilia, Arcispedale SMaria Nuova IRCCS, Pulm Unit, Dept Med Specialties, Reggio Emilia, Italy.
    Viart, Frederic
    Adv Solut Accelerator, Clapiers, France.
    Vieg, Giovanni
    CNR, Pulm Environm Epidemiol Unit, Inst Clin Physiol, Pisa, Italy;CNR, Inst Biomed & Mol Immunol A Monroy, Palermo, Italy.
    Wallace, Dana
    Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA.
    Wagenmann, Martin
    Univ Klinikum Dusseldorf, HNO Klin, Dept Otorhinolaryngol, Dusseldorf, Germany.
    Wang, De Y.
    Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore, Singapore.
    Waserman, Susan
    McMaster Univ, Dept Med Clin Immunol & Allergy, Hamilton, ON, Canada.
    Wickman, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Williams, Dennis M.
    Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
    Wong, Gary
    CHUL, Malad Infect & Immunitaires, Quebec City, PQ, Canada.
    Wroczynski, Piotr
    Warsaw Med Univ, Div Lab Med, Fac Pharm, Dept Biochem & Clin Chem, Warsaw, Poland.
    Yiallouros, Panayiotis K.
    Cyprus Univ Technol, Cyprus Int Inst Environm & Publ Hlth Assoc Harvar, Limassol, Cyprus;Hosp Archbishop Makarios III, Dept Pediat, Nicosia, Cyprus.
    Yorgancioglu, Arzu
    Celal Bayar Univ, Fac Med, Dept Pulm Dis, Manisa, Turkey.
    Yusuf, Osman M.
    Allergy & Asthma Inst, Islamabad, Pakistan.
    Zar, Heahter J.
    Red Cross Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa;Univ Cape Town, MRC, Unit Child & Adolescent Hlth, Cape Town, South Africa.
    Zeng, Stephane
    Bull DSAS, Echirolles, France.
    Zernotti, Mario
    Univ Catolica Cordoba, Cordoba, Argentina.
    Zhang, Luo
    Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China;Beijing Inst Otolaryngol, Beijing, Peoples R China.
    Zhong, Nan S.
    Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.
    Zidarn, Mihaela
    Univ Clin Resp & Allerg Dis, Golnik, Slovenia.
    Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases2019In: Clinical and Translational Allergy, ISSN 2045-7022, E-ISSN 2045-7022, Vol. 9, article id 44Article, review/survey (Refereed)
    Abstract [en]

    Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy.

    Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Sante as a Good Practice in the field of digitally-enabled, integrated, person-centred care.

    Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.

  • 56.
    Bousquet, J.
    et al.
    CHRU Arnaud Villeneuve, Fdn Partenariale FMC VIA LR, MACVIA France, Montpellier, France; VIMA Ageing Chron Dis Epidemiol Publ Hlth App, INSERM U, Villejuif, France; Univ Versailles St Quentin en Yvelines, UMRS, Montigny Le Bretonneux, France; Euforea, Brussels, Belgium; Humboldt Univ, Berlin Inst Hlth, Comprehens Allergy Ctr, Berlin, Germany; Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany.
    Wickman, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Zurkuhlen, A.
    Gesundheitsregion KölnBonn ‑ HRCB Projekt GmbH, Kohln, Germany.
    Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma2019In: Clinical and Translational Allergy, ISSN 2045-7022, E-ISSN 2045-7022, Vol. 9, article id 16Article, review/survey (Refereed)
    Abstract [en]

    Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.

    Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.

    Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors.

    Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.

    EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour).

    Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.

  • 57. Bousquet, Jean
    et al.
    Hellings, Peter W
    Agache, Ioana
    Amat, Flore
    Annesi-Maesano, Isabella
    Ansotegui, Ignacio J
    Anto, Josep M
    Bachert, Claus
    Bateman, Eric D
    Bedbrook, Anna
    Bennoor, Kazi
    Bewick, Mickael
    Bindslev-Jensen, Carsten
    Bosnic-Anticevich, Sinthia
    Bosse, Isabelle
    Brozek, Jan
    Brussino, Luisa
    Canonica, Giorgio W
    Cardona, Victoria
    Casale, Thomas
    Cepeda Sarabia, Alfonso M
    Chavannes, Niels H
    Cecchi, Lorenzo
    Correia de Sousa, Jaime
    Costa, Elisio
    Cruz, Alvaro A
    Czarlewski, Wienczyslawa
    De Carlo, Giuseppe
    De Feo, Giulia
    Demoly, Pascal
    Devillier, Philippe
    Dykewicz, Mark S
    El-Gamal, Yehia
    Eller, Esben E
    Fonseca, Joao A
    Fontaine, Jean-François
    Fokkens, Wytske J
    Guzmán, Maria-Antonieta
    Haahtela, Tari
    Illario, Maddalena
    Ivancevich, Juan-Carlos
    Just, Jocelyne
    Kaidashev, Igor
    Khaitov, Musa
    Kalayci, Omer
    Keil, Thomas
    Klimek, Ludger
    Kowalski, Marek L
    Kuna, Piotr
    Kvedariene, Violeta
    Larenas-Linnemann, Desiree
    Laune, Daniel
    Le, Lan T T
    Carlsen, Karin Lodrup
    Lourenço, Olga
    Mahboub, Bassam
    Mair, Alpana
    Menditto, Enrica
    Milenkovic, Branislava
    Morais-Almeida, Mario
    Mösges, Ralph
    Mullol, Joaquim
    Murray, Ruth
    Naclerio, Robert
    Namazova-Baranova, Leyla
    Novellino, Ettore
    O'Hehir, Robyn E
    Ohta, Ken
    Okamoto, Yoshitaka
    Okubo, Kimi
    Onorato, Gabrielle L
    Palkonen, Susanna
    Panzner, Petr
    Papadopoulos, Nikos G
    Park, Hae-Sim
    Paulino, Ema
    Pawankar, Ruby
    Pfaar, Oliver
    Plavec, Davor
    Popov, Ted A
    Potter, Paul
    Prokopakis, Emmanuel P
    Rottem, Menachem
    Ryan, Dermot
    Salimäki, Johanna
    Samolinski, Boleslaw
    Sanchez-Borges, Mario
    Schunemann, Holger J
    Sheikh, Aziz
    Sisul, Juan-Carlos
    Rajabian-Söderlund, Rojin
    Sooronbaev, Talant
    Stellato, Cristiana
    To, Teresa
    Todo-Bom, Ana-Maria
    Tomazic, Peter-Valentin
    Toppila-Salmi, Sanna
    Valero, Antonio
    Valiulis, Arunas
    Valovirta, Erkka
    Ventura, Maria-Teresa
    Wagenmann, Martin
    Wang, De Yun
    Wallace, Dana
    Waserman, Susan
    Wickman, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Yorgancioglu, Arzu
    Zhang, Luo
    Zhong, Nanshan
    Zidarn, Mihaela
    Zuberbier, Torsten
    Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology.2019In: Journal of Allergy and Clinical Immunology, ISSN 0091-6749, E-ISSN 1097-6825, Vol. 143, no 3, p. 864-879Article in journal (Refereed)
    Abstract [en]

    Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.

  • 58.
    Brodd, Katarina Strand
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Replik från Katarina Strand Brodd: Målet är tydliga rutiner för sena aborter2017In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 114, article id pii: ESZRArticle in journal (Other academic)
  • 59.
    Brough, H. A.
    et al.
    Kings Coll London, Guys Hosp, Sch Life Course Sci, Paediat Allergy Grp,Dept Women & Childrens Heath, London, England;Guys & St Thomass NHS Fdn Trust, Childrens Allergy Serv, London, England;Kings Coll London, Guys Hosp, Sch Immunol & Microbial Sci, Paediat Allergy Grp, London, England.
    Kull, I.
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden;Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden;Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden;Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden.
    Richards, K.
    Kings Coll London, Guys Hosp, Sch Life Course Sci, Paediat Allergy Grp,Dept Women & Childrens Heath, London, England;Kings Coll London, Guys Hosp, Sch Immunol & Microbial Sci, Paediat Allergy Grp, London, England.
    Hallner, E.
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden;Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden.
    Söderhäll, C.
    Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden;Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden;Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
    Douiri, A.
    Kings Coll London, Div Hlth & Social Care Res, London, England.
    Penagos, M.
    Kings Coll London, Guys Hosp, Sch Life Course Sci, Paediat Allergy Grp,Dept Women & Childrens Heath, London, England;Kings Coll London, Guys Hosp, Sch Immunol & Microbial Sci, Paediat Allergy Grp, London, England.
    Melen, E.
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden;Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden;Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden.
    Bergström, A.
    Karolinska Inst, Inst Environm Med, Stockholm, Sweden;Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden;Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden.
    Turcanu, V.
    Kings Coll London, Guys Hosp, Sch Life Course Sci, Paediat Allergy Grp,Dept Women & Childrens Heath, London, England;Kings Coll London, Guys Hosp, Sch Immunol & Microbial Sci, Paediat Allergy Grp, London, England.
    Wickman, Magnus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
    Lack, G.
    Kings Coll London, Guys Hosp, Sch Life Course Sci, Paediat Allergy Grp,Dept Women & Childrens Heath, London, England;Guys & St Thomass NHS Fdn Trust, Childrens Allergy Serv, London, England;Kings Coll London, Guys Hosp, Sch Immunol & Microbial Sci, Paediat Allergy Grp, London, England.
    Environmental peanut exposure increases the risk of peanut sensitization in high-risk children2018In: Clinical and Experimental Allergy, ISSN 0954-7894, E-ISSN 1365-2222, Vol. 48, no 5, p. 586-593Article in journal (Refereed)
    Abstract [en]

    Background: High household peanut consumption is associated with the development of peanut allergy, especially when peanut allergic cases are compared against atopic controls; thus, environmental peanut exposure (EPE) may be a risk factor for peanut sensitization and allergy. In this study, we explored the relationship between EPE and school-age peanut sensitization in a population-based cohort.

    Methods: Maternal bed dust was collected postnatally, and EPE was quantified using a polyclonal peanut ELISA. Peanut sensitization was assessed by specific IgE to peanut extract and sIgE to peanut protein component allergens Ara h 1, 2 or 3 >= 0.35kU/L (primary peanut sensitization). Initial nested case-control analysis was performed comparing peanut-sensitized cases against high-risk controls (matched for parental atopy) (n = 411) using a conditional regression analysis. This was followed by whole cohort analysis (n = 1878) comparing EPE against peanut sIgE sensitization at ages 4 and 8 years using generalized estimating equations and against primary peanut sensitization at age 8 years using a logistic regression model. Finally, a subgroup analysis was performed comparing the impact of EPE in peanut-sensitized vs egg-sensitized, peanut-tolerant individuals using logistic regression analysis. Levels of EPE were compared between groups using the Mann-Whitney U test.

    Results: In the nested case-control analysis, a higher level of EPE around birth was associated with peanut-specific IgE sensitization at age 4 years (OR=1.41, 95% CI:1.05-1.90) and primary peanut sensitization at age 8 years (OR=2.11, 95% CI:1.38-3.22) compared against high-risk controls. When the whole BAMSE cohort was assessed, EPE was no longer associated with peanut sensitization; however, on subgroup analysis, EPE was associated with primary peanut sensitization when compared against egg-sensitized peanut-tolerant controls with an adjusted odds ratio of 1.44 per unit EPE (95% CI:1.06-1.94). There was no significant interaction between EPE and FLG loss-of-function mutations, egg sensitization at age 4 years, infantile eczema or parental atopy on peanut sensitization.

    Conclusions: Higher levels of environmental exposure to peanut in the first few months of life appear to increase the probability of developing school-age peanut sensitization in atopic children (based on egg sensitization and parental atopy).

  • 60. Brunstein, Claudio G
    et al.
    Pasquini, Marcelo C
    Kim, Soyoung
    Fei, Mingwei
    Adekola, Kehinde
    Ahmed, Ibrahim
    Aljurf, Mahmoud
    Agrawal, Vaibhav
    Auletta, Jeffrey J
    Battiwalla, Minoo
    Bejanyan, Nelli
    Bubalo, Joseph
    Cerny, Jan
    Chee, Lynette
    Ciurea, Stefan O
    Freytes, Cesar
    Gadalla, Shahinaz M
    Gale, Robert Peter
    Ganguly, Siddhartha
    Hashmi, Shahrukh K
    Hematti, Peiman
    Hildebrandt, Gerhard
    Holmberg, Leona A
    Lahoud, Oscar B
    Landau, Heather
    Lazarus, Hillard M
    de Lima, Marcos
    Mathews, Vikram
    Maziarz, Richard
    Nishihori, Taiga
    Norkin, Maxim
    Olsson, Richard
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Reshef, Ran
    Rotz, Seth
    Savani, Bipin
    Schouten, Harry C
    Seo, Sachiko
    Wirk, Baldeep M
    Yared, Jean
    Mineishi, Shin
    Rogosheske, John
    Perales, Miguel-Angel
    Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation2019In: Biology of blood and marrow transplantation, ISSN 1083-8791, E-ISSN 1523-6536, Vol. 25, no 3, p. 480-487Article in journal (Refereed)
    Abstract [en]

    Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m2. Dose adjustment was defined as a reduction in standard dosing ≥ 20%, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n = 1696) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324 patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on overall survival (P = .894) and treatment-related mortality (TRM) (P = .62), progression (P = .12), and progression-free survival (PFS; P = .178). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect survival (P = .176), TRM (P = .802), relapse (P = .633), or PFS (P = .812). No center effect was observed in lymphoma. This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not influence mortality. These results do not support adjusting chemotherapy dose in this population.

  • 61.
    Burke, Michael J.
    et al.
    Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Milwaukee, WI 53226 USA.;Childrens Hosp Wisconsin, Milwaukee, WI 53226 USA..
    Verneris, Michael R.
    Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA..
    Le Rademacher, Jennifer
    Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI 53226 USA..
    He, Wensheng
    Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA..
    Abdel-Azim, Hisham
    Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA..
    Abraham, Allistair A.
    Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Div Blood & Marrow Transplantat, Washington, DC 20010 USA..
    Auletta, Jeffery J.
    Nationwide Childrens Hosp, Div Hematol Oncol Bone Marrow Transplantat & Infe, Columbus, OH USA..
    Ayas, Mouhab
    King Faisal Specialist Hosp & Res Ctr, Dept Pediat Hematol Oncol, Riyadh, Saudi Arabia..
    Brown, Valerie I.
    Penn State Hershey Childrens Hosp, Dept Pediat, Div Pediat Oncol Hematol, Hershey, PA USA.;Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA..
    Cairo, Mitchell S.
    New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA..
    Chan, Ka Wah
    Texas Transplant Inst, Dept Pediat, San Antonio, TX USA..
    Diaz Perez, Miguel A.
    Hosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain..
    Dvorak, Christopher C.
    Univ Calif San Francisco, Dept Pediat, Med Ctr, San Francisco, CA USA..
    Egeler, R. Maarten
    Hosp Sick Children, Dept Hematol Oncol, Toronto, ON M5G 1X8, Canada..
    Eldjerou, Lamis
    Univ Florida, Dept Pediat, Gainesville, FL USA..
    Frangoul, Haydar
    Vanderbilt Univ, Dept Pediat, Div Hematol Oncol, Sch Med, Nashville, TN USA..
    Guilcher, Gregory M. T.
    Alberta Childrens Prov Gen Hosp, Sect Paediat Oncol & Blood & Marrow Transplant, Calgary, AB, Canada..
    Hayashi, Robert J.
    Washington Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, St Louis, MO 63110 USA..
    Ibrahim, Ahmed
    Makassed Gen Hosp, Dept Hematol Oncol, Beiruit, Lebanon..
    Kasow, Kimberly A.
    Univ N Carolina, Dept Pediat, Div Hematol Oncol, Chapel Hill, NC USA..
    Leung, Wing H.
    St Jude Childrens Res Hosp, Div Bone Marrow Transplantat, Memphis, TN 38105 USA..
    Olsson, Richard F.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.
    Pulsipher, Michael A.
    Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA..
    Shah, Niketa
    Mayo Clin Arizona, Dept Pediat, Div Hematol Oncol, Phoenix, AZ USA.;Phoenix Childrens Hosp, Phoenix, AZ USA..
    Shah, Nirali N.
    Natl Canc Inst NIH, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD USA..
    Thiel, Elizabeth
    Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA..
    Talano, Julie-An
    Med Coll Wisconsin, Dept Pediat, Div Hematol Oncol Blood & Marrow Transplant, Milwaukee, WI 53226 USA.;Childrens Hosp Wisconsin, Milwaukee, WI 53226 USA..
    Kitko, Carrie L.
    Vanderbilt Univ, Dept Pediat, Stem Cell Transplant Program, Nashville, TN USA..
    Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research2015In: Biology of blood and marrow transplantation, ISSN 1083-8791, E-ISSN 1523-6536, Vol. 21, no 12, p. 2154-2159Article in journal (Refereed)
    Abstract [en]

    Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described. Two hundred twenty-nine children with T-ALL in second complete remission (CR2) received an HCT after myeloablative conditioning between 2000 and 2011 and were reported to the Center for International Blood and Marrow Transplant Research. Median age was 10 years (range, 2 to 18). Donor source was umbilical cord blood (26%), matched sibling bone marrow (38%), or unrelated bone marrow/peripheral blood (36%). Acute (grades II to IV) and chronic graft-versus-host disease occurred in, respectively, 35% (95% confidence interval [CI], 27% to 45%) and 26% (95% CI, 20% to 33%) of patients. Transplant-related mortality at day 100 and 3-year relapse rates were 13% (95% CI, 9% to 18%) and 30% (95% CI, 24% to 37%), respectively. Three-year overall survival and disease-free survival rates were 48% (95% CI, 41% to 55%) and 46% (95% CI, 39% to 52%), respectively. In multivariate analysis, patients with bone marrow relapse, with or without concurrent extramedullary relapse before HCT, were most likely to relapse (hazard ratio, 3.94; P =.005) as compared with isolated extramedullary disease. In conclusion, HCT for pediatric T-ALL in CR2 demonstrates reasonable and durable outcomes, and consideration for HCT is warranted. (c) 2015 American Society for Blood and Marrow Transplantation.

  • 62. Calissendorff, Jan
    et al.
    Mikulski, Emil
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Larsen, Erik H
    Möller, Marika
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    A Prospective Investigation of Graves' Disease and Selenium: Thyroid Hormones, Auto-Antibodies and Self-Rated Symptoms.2015In: European thyroid journal, ISSN 2235-0640, Vol. 4, no 2, p. 93-8Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: In Graves' thyrotoxicosis tachycardia, weight loss and mental symptoms are common. Recovery takes time and varies between patients. Treatment with methimazole reduces thyroid hormone levels. According to previous research, this reduction has been faster if selenium (Se) is added.

    OBJECTIVE: The objective was to investigate whether supplementing the pharmacologic treatment with Se could change the immune mechanisms, hormone levels and/or depression and anxiety.

    METHODS: We prospectively investigated 38 patients with initially untreated thyrotoxicosis by measuring the thyroid-stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3), thyroid receptor antibodies and thyroid peroxidase auto-antibodies before medication and at 6, 18 and 36 weeks after commencing treatment with methimazole and levo-thyroxine, with a randomized blinded oral administration of 200 µg Se/day or placebo. The selenoprotein P concentration was determined in plasma at inclusion and after 36 weeks. The patients were also assessed with questionnaires about depression, anxiety and self-rated symptoms before medication was started and after 36 weeks.

    RESULTS: FT4 decreased more in the Se group at 18 weeks (14 vs. 17 pmol/l compared to the placebo group, p = 0.01) and also at 36 weeks (15 vs. 18 pmol/l, p = 0.01). The TSH increased more in the Se group at 18 weeks (0.05 vs. 0.02 mIU/l, p = 0.04). The depression and anxiety scores were similar in both groups. In the Se group, the depression rates correlated negatively with FT3 and positively with TSH. This was not seen in the placebo group.

    CONCLUSIONS: Se supplementation can enhance biochemical restoration of hyperthyroidism, but whether this could shorten clinical symptoms of thyrotoxicosis and reduce mental symptoms must be investigated further.

  • 63. Carlsson, Anja M
    et al.
    Ngasala, Billy E
    Dahlström, Sabina
    Membi, Christopher
    Veiga, Isabel M
    Rombo, Lars
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Abdulla, Salim
    Premji, Zul
    Gil, J Pedro
    Björkman, Anders
    Mårtensson, Andreas
    Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria2011In: Malaria Journal, ISSN 1475-2875, E-ISSN 1475-2875, Vol. 10, p. 380-Article in journal (Refereed)
    Abstract [en]

    BACKGROUND:

    This study aimed to explore Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment with artemisinin-based combination therapy in children with clinical malaria in a high transmission area in Africa.

    METHODS:

    A total of 50 children aged 1-10 years with acute uncomplicated P. falciparum malaria in Bagamoyo District, Tanzania, were enrolled. Participants were hospitalized and received supervised standard treatment with artemether-lumefantrine according to body weight in six doses over 3 days. Blood samples were collected 11 times, i.e. at time of diagnosis (-2 h) and 0, 2, 4, 8, 16, 24, 36, 48, 60 and 72 h after initiation of treatment. Parasite population dynamics were assessed using nested polymerase chain reaction (PCR)-genotyping of merozoite surface protein (msp) 1 and 2.

    RESULTS:

    PCR-analyses from nine sequential blood samples collected after initiation of treatment identified 20 and 21 additional genotypes in 15/50 (30%) and 14/50 (28%) children with msp1 and msp2, respectively, non-detectable in the pre-treatment samples (-2 and 0 h combined). Some 15/20 (75%) and 14/21 (67%) of these genotypes were identified within 24 h, whereas 17/20 (85%) and 19/21 (90%) within 48 h for msp1 and msp2, respectively. The genotype profile was diverse, and varied considerably over time both within and between patients, molecular markers and their respective families.

    CONCLUSION:

    PCR analyses from multiple blood samples collected during the early treatment phase revealed a complex picture of parasite sub-populations. This underlines the importance of interpreting PCR-outcomes with caution and suggests that the present use of PCR-adjustment from paired blood samples in anti-malarial drug trials may overestimate assessment of drug efficacy in high transmission areas in Africa.The study is registered at http://www.clinicaltrials.gov with identifier NCT00336375.

  • 64.
    Carlsson, Lars
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Center for Clinical Research Dalarna.
    Englund, Lars
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Center for Clinical Research Dalarna.
    Hallqvist, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Wallman, Thorne
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Early multidisciplinary assessment was associated with longer periods of sick leave: A randomized controlled trial in a primary health care centre2013In: Scandinavian Journal of Primary Health Care, ISSN 0281-3432, E-ISSN 1502-7724, Vol. 31, no 3, p. 141-146Article in journal (Refereed)
    Abstract [en]

    Objective

    To study the effects on sick leave from an early multidisciplinary assessment at a primary health care centre. Design. Randomized controlled trial.

    Setting

    Patients who saw GPs at a primary health care centre in mid-Sweden and asked for a sickness certificate for psychiatric or musculoskeletal diagnoses were invited to participate. Patients included were sick-listed for less than four weeks; 33 patients were randomized either to an assessment within a week by a physiotherapist, a psychotherapist, and an occupational therapist or to "standard care". The therapists used methods and tools they normally use in their clinical work.

    Main outcome measure

    Proportion of patients still sick-listed three months after randomization, total and net days on sick leave, and proportion who were on part-time sick leave.

    Results

    At follow-up after three months, in contrast to the pre-trial hypothesis, there was a trend toward a higher proportion of patients still sick-listed in the intervention group (7/18) as compared with the control group (3/15). The intervention group also had significantly longer sick-listing periods (mean 58 days) than the control group (mean 36 days) (p = 0.038). The proportion of patients who were part time sick-listed was significantly higher in the intervention group (10/18) than in the control group (2/15) (p = 0.027).

    Conclusions

    In this study an early multidisciplinary assessment was associated with longer periods on sick leave and more individuals on part-time sick leave.

  • 65.
    Carlsson, Lars
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine. Centre for Clinical Research Dalarna, Uppsala University, Falun, Sweden.
    Lytsy, Per
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social Medicine.
    Anderzén, Ingrid
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Social Medicine.
    Hallqvist, Johan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Wallman, Thorne
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Gustavsson, Catharina
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine. Centre for Clinical Research Dalarna, Uppsala University, Falun, Sweden.
    Motivation for return to work and actual return to work among people on long-term sick leave due to pain syndrome or mental health conditionsManuscript (preprint) (Other academic)
  • 66.
    Carlsson, Lars
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Lännerström, Linda
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Wallman, Thorne
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Holmström, Inger Knutsson
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Health Services Research.
    General practitioners' perceptions of working with the certification of sickness absences following changes in the Swedish social security system: a qualitative focus-group study2015In: BMC Family Practice, ISSN 1471-2296, E-ISSN 1471-2296, Vol. 16, article id 21Article in journal (Refereed)
    Abstract [en]

    Background: Many physicians in Sweden, as well as in other countries, find the matter of certification of sickness absence (COSA) particularly burdensome. The issuing of COSAs has also been perceived as a work-environment problem among physicians. Among general practitioners (GPs) are the highest proportion of physicians in Sweden who experience difficulties with COSA. Swedish authorities have created several initiatives, by changing the social security system, to improve the rehabilitation of people who are ill and decrease the number of days of sick leave used. The aim of this study was to describe how GPs in Sweden perceive their work with COSA after these changes. Methods: A descriptive design with a qualitative, inductive focus-group discussion (FGD) approach was used. Results: Four categories emerged from the analysis of FGDs with GPs in Sweden: 1) Physicians' difficulties in their professional role; 2) Collaboration with other professionals facilitates the COSA; 3) Physicians' approach in relation to the patient; 4) An easier COSA process. Conclusions: Swedish GPs still perceived COSA to be a burdensome task. However, system changes in recent years have facilitated work related to COSA. Cooperation with other professionals on COSA was perceived positively.

  • 67.
    Carlsson, Tommy
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Clinical Psychology in Healthcare. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health.
    Axelsson, Ove
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Obstetrics and Gynaecology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Patient Information Websites About Medically Induced Second-Trimester Abortions: A Descriptive Study of Quality, Suitability, and Issues2017In: Journal of Medical Internet Research, ISSN 1438-8871, E-ISSN 1438-8871, Vol. 19, no 1, article id e8Article in journal (Refereed)
    Abstract [en]

    Background: Patients undergoing medically induced second-trimester abortions feel insufficiently informed and use the Web for supplemental information. However, it is still unclear how people who have experience with pregnancy termination appraise the quality of patient information websites about medically induced second-trimester abortions, whether they consider the websites suitable for patients, and what issues they experience with the websites.

    Objective: Our objective was to investigate the quality of, suitability of, and issues with patient information websites about medically induced second-trimester abortions and potential differences between websites affiliated with the health care system and private organizations.

    Methods: We set out to answer the objective by using 4 laypeople who had experience with pregnancy termination as quality assessors. The first 50 hits of 26 systematic searches were screened (N=1300 hits) using search terms reported by the assessors. Of these hits, 48% (628/1300) were irrelevant and 51% (667/1300) led to websites about medically induced second-trimester abortions. After correcting for duplicate hits, 42 patient information websites were included, 18 of which were affiliated with the health care system and 24 with private organizations. The 4 assessors systematically assessed the websites with the DISCERN instrument (total score range 16-80), the Ensuring Quality Information for Patients (EQIP) tool (total score range 0-100), as well as questions concerning website suitability and perceived issues.

    Results: The interrater reliability was 0.8 for DISCERN and EQIP, indicating substantial agreement between the assessors. The total mean score was 36 for DISCERN and 40 for EQIP, indicating poor overall quality. Websites from the health care system had greater total EQIP (45 vs 37, P>.05) and reliability scores (22 vs 20, P>.05). Only 1 website was recommended by all assessors and 57% (24/42) were rated as very unsuitable by at least one assessor. The most reported issues with the websites involved lack of information (76%, 32/42), and poor design (36%, 15/42).

    Conclusions: The high number of irrelevant hits and poor quality of patient information websites are considerable issues that must be addressed and considered when consulting patients awaiting medically induced second-trimester abortions. In clinical encounters, health professionals should initiate discussions concerning websites about medically induced second-trimester abortions and inform patients about the issues and quality deficits associated with these websites.

  • 68.
    Carlsson, Tommy
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Research group (Dept. of women´s and children´s health), Clinical Psychology in Healthcare.
    Melander, Marttala Ulla
    Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Languages, Department of Scandinavian Languages.
    Wadensten, Barbro
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Caring Sciences.
    Bergman, Gunnar
    Institutionen för Kvinnors och Barns Hälsa, Karolinska Institutet.
    Axelsson, Ove
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Research group (Dept. of women´s and children´s health), Obstetric research. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Mattsson, Elisabet
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health, Research group (Dept. of women´s and children´s health), Clinical Psychology in Healthcare. Institutionen för Vårdvetenskap, Ersta Sköndal Bräcke Högskola.
    Quality of Patient Information Websites About Congenital Heart Defects: Mixed-Methods Study of Perspectives Among Individuals With Experience of a Prenatal Diagnosis2017In: Interactive Journal of Medical Research, E-ISSN 1929-073X, Vol. 6, no 2, article id e15Article in journal (Refereed)
    Abstract [en]

    Background: When a heart defect is prenatally diagnosed in the fetus, expectant parents experience a great need for information about various topics. After the diagnosis, the Web is used for supplemental information, and the scarcity of research calls attention to the need to explore patient information websites from the perspectives of the intended consumers.

    Objective: The overarching aim of this study was to explore the quality of Swedish patient information websites about congenital heart defects, from the perspectives of individuals with experience of a prenatal diagnosis of congenital heart defect in the fetus.

    Methods: This was a mixed-methods study of websites identified through systematic searches in the two most used Web-based search engines. Of the total 80 screened hits, 10 hits led to patient information websites about congenital heart defects. A quality assessment tool inspired by a previous study was used to evaluate each website’s appearance, details, relevance, suitability, information about treatment choices, and overall quality. Answers were given on a 5-point Likert scale, ranging from 1, representing the lowest score, to 5, representing the highest score. Each website was assessed individually by persons with experience of continued (n=4) and terminated (n=5) pregnancy following a prenatal diagnosis. Assessments were analyzed with Kendall’s coefficient of concordance W, Mann-Whitney U test, Friedman’s test, and a Wilcoxon-Nemenyi-McDonald-Thompson test. In addition, each assessor submitted written responses to open-ended questions in the quality assessment tool, and two joint focus group discussions were conducted with each group of assessors. The qualitative data were analyzed with inductive manifest content analysis.

    Results: Assessments represented a low score (median=2.0) for treatment choices and moderate scores (median=3.0) for appearance, details, relevance, suitability, and overall quality. No website had a median of the highest achievable score for any of the questions in the quality assessment tool. Medians of the lowest achievable score were found in questions about treatment choices (n=4 websites), details (n=2 websites), suitability (n=1 website), and overall quality (n=1 website). Websites had significantly different scores for appearance (P=.01), details (P<.001), relevance (P<.001), suitability (P<.001), treatment choices (P=.04), and overall quality (P<.001). The content analysis of the qualitative data generated six categories: (1) advertisements, (2) comprehensiveness, (3) design, (4) illustrations and pictures, (5) language, and (6) trustworthiness. Various issues with the included websites were highlighted, including the use of inappropriate advertisements, biased information, poor illustrations, complex language, and poor trustworthiness.

    Conclusions: From the perspectives of the intended consumers, patient information websites about congenital heart defects are, to a large extent, inadequate tools for supplemental information following a prenatal diagnosis. Health professionals should initiate discussions with patients about their intentions to use the Web, inform them about the varied quality in the Web-based landscape, and offer recommendations for appropriate Web-based sources.

  • 69.
    Castegren, Markus
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Infectious Diseases.
    Jonasson, Mikaela
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Castegren, Sara
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Lipcsey, Miklós
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.
    Sjölin, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Infectious Diseases.
    Initial levels of organ failure, microbial findings and mortality in intensive care-treated primary, secondary and tertiary sepsis2015In: CRITICAL CARE AND RESUSCITATION, ISSN 1441-2772, Vol. 17, no 3, p. 174-181Article in journal (Refereed)
    Abstract [en]

    Objective: Analysis of whether patients with primary, secondary and tertiary sepsis, defined by the presence or absence of recent systemic inflammation-inducing events before the onset of sepsis, differ in clinical presentation, microbiological test results, treatment received and outcome. Design, setting and participants: A retrospective observational study in a single, general intensive care unit, of all patients treated for severe sepsis or septic shock from 2006 to 2011. Patients with haematological malignancies, with immunosuppressive diseases or being treated with immunosuppressive drugs were excluded. Interventions: None. Main outcome measures: Sequential Organ Failure Assessment score, incidence of organ failure, microbiological results of blood cultures and mortality. Results: We included 213 patients, who were classified as having primary (n = 121), secondary (n = 65) or tertiary sepsis (n = 27). The groups differed significantly in SOFA score, the incidence of kidney failure and coagulation failure at onset of sepsis in the ICU, as well as in blood culture findings. No differences in 7-day or 28-day mortality were seen, but the time of death occurred earlier among non-survivors in the primary sepsis group. Conclusions: Inflammatory insults before the onset of sepsis affect the clinical picture, blood microbial findings, and in non-survivors, the time of death. These results could, if validated in a prospective study, form a basis for a novel and simple strategy for stratifying patients in clinical studies for immunomodulation therapies in sepsis.

  • 70.
    Casulo, Carla
    et al.
    Univ Rochester, Wilmot Canc Inst, New York, NY USA.
    Friedberg, Jonathan W.
    Univ Rochester, Wilmot Canc Inst, New York, NY USA.
    Ahn, Kwang W.
    Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
    Flowers, Christopher
    Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA.
    DiGilio, Alyssa
    Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA.
    Smith, Sonali M.
    Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA.
    Ahmed, Sairah
    Univ MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA.
    Inwards, David
    Mayo Clin, Div Hematol, Rochester, MN USA.
    Aljurf, Mahmoud
    King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riydah, Saudi Arabia.
    Chen, Andy, I
    Oregon Hlth & Sci Univ, Blood & Marrow Transplant Program, Portland, OR 97201 USA.
    Choe, Hannah
    Weill Cornell Med Coll, Blood & Marrow Transplant Program, New York, NY USA.
    Cohen, Jonathon
    Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA.
    Copelan, Edward
    Carolinas HealthCare Syst, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA.
    Farooq, Umar
    Univ Iowa, Dept Med, Iowa City, IA 52242 USA.
    Fenske, Timothy S.
    Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
    Freytes, Cesar
    Texas Transplant Inst, Blood & Marrow Transplant Program, San Antonio, TX USA.
    Gaballa, Sameh
    Thomas Jefferson Univ Hosp, Blood & Marrow Transplant Program, Philadelphia, PA 19107 USA.
    Ganguly, Siddhartha
    Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS 66103 USA.
    Jethava, Yogesh
    Univ Arkansas Med Sci, Blood & Marrow Transplant Program, Little Rock, AR 72205 USA.
    Kamble, Rammurti T.
    Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA.
    Kenkre, Vaishalee P.
    Univ Wisconsin, Div Hematol & Oncol, Madison, WI USA.
    Lazarus, Hillard
    Univ Hosp Cleveland, Seidman Canc Ctr, Med Ctr, Cleveland, OH 44106 USA.
    Lazaryan, Aleksandr
    Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA.
    Olsson, Richard
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.
    Rezvani, Andrew R.
    Stanford Hlth Care, Blood & Marrow Transplant Program, Stanford, CA USA.
    Rizzieri, David
    Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.
    Seo, Sachiko
    East Hosp, Natl Canc Res Ctr, Chiba, Japan.
    Shah, Gunjan L.
    Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA.
    Shah, Nina
    Univ MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Div Canc Med, Houston, TX USA.
    Solh, Melham
    Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.
    Sureda, Anna
    Inst Catala Oncol Hosp, Hematol Dept, Barcelona, Spain.
    William, Basem
    Ohio State Med Ctr, James Canc Ctr, Columbus, OH USA.
    Cumpston, Aaron
    West Virginia Univ Hosp, Blood & Marrow Transplant Program, Morgantown, WV USA.
    Zelenetz, Andrew D.
    Mem Sloan Kettering Canc Ctr, Blood & Marrow Transplant Program, 1275 York Ave, New York, NY 10021 USA.
    Link, Brian K.
    Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
    Hamadani, Mehdi
    Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI 53226 USA.
    Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis2018In: Biology of blood and marrow transplantation, ISSN 1083-8791, E-ISSN 1523-6536, Vol. 24, no 6, p. 1163-1171Article in journal (Refereed)
    Abstract [en]

    Patients with follicular lymphoma (FL) experiencing early therapy failure (ETF) within 2 years of frontline chemoimmunotherapy have poor overall survival (OS). We analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National LymphoCare Study (NLCS) to determine whether autologous hematopoietic cell transplant (autoHCT) can improve outcomes in this high-risk FL subgroup. ETF was defined as failure to achieve at least partial response after frontline chemoimmunotherapy or lymphoma progression within 2 years of frontline chemoimmunotherapy. We identified 2 groups: the non-autoHCT cohort (patients from the NLCS with ETF not undergoing autoHCT) and the autoHCT cohort (CIBMTR patients with ETF undergoing autoHCT). All patients received rituximab-based chemotherapy as frontline treatment; 174 non-autoHCT patients and 175 autoHCT patients were identified and analyzed. There was no difference in 5-year OS between the 2 groups (60% versus 67%, respectively; P = .16). A planned subgroup analysis showed that patients with ETF receiving autoHCT soon after treatment failure (≤1 year of ETF; n = 123) had higher 5-year OS than those without autoHCT (73% versus 60%, P = .05). On multivariate analysis, early use of autoHCT was associated with significantly reduced mortality (hazard ratio, .63; 95% confidence interval, .42 to .94; P = .02). Patients with FL experiencing ETF after frontline chemoimmunotherapy lack optimal therapy. We demonstrate improved OS when receiving autoHCT within 1 year of treatment failure. Results from this unique collaboration between the NLCS and CIBMTR support consideration of early consolidation with autoHCT in select FL patients experiencing ETF.

  • 71.
    Catharina, Frank
    et al.
    Karolinska Institutet.
    Lindbäck, Camilla
    Mälardalens högskola.
    Christina, Takman
    Karolinska Institutet.
    Nordgren, Lena
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Healthcare professionals’ perceptions of their work with patients of working age with heart failure2017In: Nordic journal of nursing research, ISSN 2057-1585, E-ISSN 2057-1593Article in journal (Refereed)
    Abstract [en]

    There is a lack of knowledge about healthcare professionals’ perspectives on rehabilitation in relation to heart failure.Still, collaboration between different professionals can impact patients. The purpose of this study was to describe healthcareprofessionals’ perceptions of their work with patients of working age with heart failure. The sample population consisted of sixnurses, one physiotherapist and one cardiologist. One individual interview and two focus-group interviews were conducted.The interviews were analyzed using qualitative content analysis. Three descriptive categories were constructed: ‘the impact ofheart failure on patients’ life situations’, ‘heart failure service’, and ‘patients’ process of returning to work’. To support patients,healthcare professionals need to find ways to combine patients’ personal needs with protocol-driven care.

  • 72.
    Cederbom, Sara
    et al.
    OsloMet Oslo Metropolitan Univ, Fac Hlth Sci, Dept Physiotherapy, Postboks 4,St Olays Plass, N-0130 Oslo, Norway.
    Arkkukangas, Marina
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Physiotherapy. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Impact of the fall prevention Otago Exercise Programme on pain among community-dwelling older adults: a short- and long-term follow-up study2019In: Clinical Interventions in Aging, ISSN 1176-9092, E-ISSN 1178-1998, Vol. 14, p. 721-726Article in journal (Refereed)
    Abstract [en]

    Background: Pain is a major public health issue among community-dwelling older adults, with a prevalence of 45-80%. In addition to being strongly associated with reduced physical function, loss of independence, psychological distress, lower quality of life, and risk of earlier death. Recent research has also found that pain in older adults is associated with a higher risk of falls, which itself is another major health concern. Long-term and high-intensity pain are predictors of chronic pain and pain-related disability. Therefore, establishing an evidence-based intervention that can reduce both pain and falls in older adults is of high importance.

    Purpose: This study aimed to investigate whether a home-based fall-preventive exercise-program can reduce pain in the target population over both the short and long term.

    Patients and methods: This was a quasi-experimental study with a 1-group pretest-posttest design. We included 119 participants who had participated in a recent 2-year fall prevention intervention in a randomized controlled trial. The intervention included exercises based on the Otago Exercise Programme (OEP), an individually tailored and prescribed program that involves home-based exercises supervised by a physiotherapist. Pain was measured using an item from the EuroQol-5D questionnaire.

    Results: Pain was significantly reduced from baseline (n=119) at 3 (n=105, p=0.003), 12 (n=96, p=0.041), and 24 (n=80, p=0.028) months following the commencement of OEP-based exercises.

    Conclusions: These results indicate that the OEP could be a suitable evidence-based program for both pain management and fall prevention among community-dwelling older people who live with pain and are at a higher risk of falling. Our study highlights an effective technique for better pain management and fall prevention in older adults.

  • 73.
    Chaudhury, Sonali
    et al.
    Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat Hematol Oncol & Stem Cell Transplanta, 225 E Chicago Ave, Chicago, IL 60611 USA..
    Sparapani, Rodney
    Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA..
    Hu, Zhen-Huan
    Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA..
    Nishihori, Taiga
    Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA..
    Abdel-Azim, Hisham
    Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA..
    Malone, Adriana
    Icahn Sch Med Mt Sinai, Bone Marrow & Stem Cell Transplantat, New York, NY 10029 USA..
    Olsson, Richard
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden.
    Hamadani, Mehdi
    Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Milwaukee, WI 53226 USA..
    Daly, Andrew
    Univ Calgary, Tom Baker Canc Ctr, Cumming Sch Med, Calgary, AB, Canada..
    Bacher, Ulrike
    Univ Canc Ctr Hamburg, Interdisciplinary Clin Stem Cell Transplantat, Hamburg, Germany..
    Wirk, Baldeep M.
    Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA..
    Kamble, Rammurti T.
    Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA..
    Gale, Robert P.
    Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England..
    Wood, William A.
    Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA..
    Hale, Gregory
    Univ S Florida, All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL 33701 USA..
    Wiernik, Peter H.
    Canc Res Fdn New York, Bronx, NY USA..
    Hashmi, Shahrukh K.
    Mayo Clin, Dept Blood & Marrow Transplantat, Rochester, MN USA..
    Marks, David
    Univ Hosp Bristol NHS Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England..
    Ustun, Celalettin
    Univ Minneapolis, Div Hematol Oncol & Transplantat, Minneapolis, MN USA..
    Munker, Reinhold
    Louisiana State Univ Hlth Shreveport, Dept Internal Med, Sect Hematol Oncol, Shreveport, LA USA..
    Savani, Bipin N.
    Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA..
    Alyea, Edwin
    Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.;Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA..
    Popat, Uday
    Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA..
    Sobecks, Ronald
    Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA..
    Kalaycio, Matt
    Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA..
    Maziarz, Richard
    Oregon Hlth & Sci Univ, Knight Canc Inst, Adult Blood & Marrow Stem Cell Transplant Program, Portland, OR 97201 USA..
    Hijiya, Nobuko
    Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat Hematol Oncol & Stem Cell Transplanta, 225 E Chicago Ave, Chicago, IL 60611 USA..
    Saber, Wael
    Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA..
    Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis2016In: Biology of blood and marrow transplantation, ISSN 1083-8791, E-ISSN 1523-6536, Vol. 22, no 6, p. 1056-1064Article in journal (Refereed)
    Abstract [en]

    Chronic myeloid leukemia (CML) in children and young adults is uncommon. Young patients have long life expectancies and low morbidity with hematopoietic cell transplantation (HCT). Prolonged tyrosine kinase inhibitor (TKI) use may cause significant morbidity. In addition, indication for HCT in patients in the first chronic phase is not established. We hence retrospectively evaluated outcomes in 449 CML patients with early disease receiving myeloablative HCT reported to the CIBMTR. We analyzed various factors affecting outcome, specifically the effect of age and pre-HCT TKI in pediatric patients (age < 18 years, n = 177) and young adults (age 18 to 29 years, n = 272) with the goal of identifying prognostic factors. Post-HCT probability rates of 5-year overall survival (OS) and leukemia-free survival (LFS) were 75% and 59%, respectively. Rates of OS and LFS were 76% and 57% in <18-year and 74% and 60% in 18- to 29-year group, respectively, by univariate analysis (P = .1 and = .6). Five-year rates of OS for HLA matched sibling donor (MSD) and bone marrow (BM) stem cell source were 83% and 80%, respectively. In multivariate analysis there was no effect of age (<18 versus 18 to 29) or pre-HCT TKI therapy on OS, LFS, transplant related mortality, or relapse. Favorable factors for OS were MSD (P < .001) and recent HCT (2003 to 2010; P = .04). LFS was superior with MSD (P < .001), BM as graft source (P = .001), and performance scores > 90 (P = .03) compared with unrelated or mismatched peripheral blood stem cells donors and recipients with lower performance scores. Older age was associated with increased incidence of chronic graft-versus-host disease (P = .0002). In the current era, HCT outcomes are similar in young patients and children with early CML, and best outcomes are achieved with BM grafts and MSD.

  • 74. Chavannes, Niels
    et al.
    Ställberg, Björn
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
    Lisspers, Karin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Clinical Epidemiology.
    Roman, Miguel
    Moran, Ana
    Langhammer, Arnulf
    Crockett, Alan
    Cave, Andrew
    Williams, Siân
    Jones, Rupert
    Tsiligianni, Ioanna
    van der Molen, Thys
    Price, David
    UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance Knowledge2010In: Primary Care Respiratory Journal, ISSN 1471-4418, E-ISSN 1475-1534, Vol. 19, no 4, p. 408-Article, review/survey (Refereed)
  • 75.
    Chen, Y-B
    et al.
    Massachusetts Gen Hosp, Yawkey 9E 9052 55 Fruit St, Boston, MA 02114 USA..
    Wang, T.
    Med Coll Wisconsin, Ctr Int Blood, Marrow Transplant Res, Dept Med, Milwaukee, WI USA.;Med Coll Wisconsin, Div Biostat, Inst Hlth & Soc, Milwaukee, WI USA..
    Hemmer, M. T.
    Med Coll Wisconsin, Ctr Int Blood, Marrow Transplant Res, Dept Med, Milwaukee, WI USA..
    Brady, C.
    Natl Marrow Donor Program Be Match, Ctr Int Blood, Marrow Transplant Res, Minneapolis, MN USA..
    Couriel, D. R.
    Marrow Transplant Program, Utah Blood, Salt Lake City, UT USA..
    Alousi, A.
    Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Stem Cell Transplantat, Houston, TX 77030 USA..
    Pidala, J.
    H Lee Moffitt Canc Ctr & Res Inst, Res Inst, Tampa, FL USA..
    Urbano-Ispizua, A.
    Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain.;Univ Barcelona, Inst Res Josep Carreras, Dept Hematol, Hosp Clin, Barcelona, Spain..
    Choi, S. W.
    Univ Michigan, Ann Arbor, MI 48109 USA..
    Nishihori, T.
    H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA..
    Teshima, T.
    Univ Hosp, Fukuoka, Japan..
    Inamoto, Y.
    Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan..
    Wirk, B.
    Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA..
    Marks, D. I.
    Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England..
    Abdel-Azim, H.
    Univ So Calif, Keck Sch Med, Marrow Transplantat, Div Hematol Oncol & Blood, Los Angeles, CA 90033 USA..
    Lehmann, L.
    Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA..
    Yu, L.
    Louisiana State Univ, Med Ctr, Div Hematol Oncol, Childrens Hosp,Ctr Canc & Blood Disorders,HSC, New Orleans, LA USA..
    Bitan, M.
    Tel Aviv Sourasky Med Ctr, Tel Aviv, Dept Pediat Hematol Oncol, Tel Aviv, Israel..
    Cairo, M. S.
    New York Med Coll, Div Pediat Hematol Oncol, Stem Cell Transplantat, Dept Pediat, Valhalla, NY USA..
    Qayed, M.
    Emory Univ, Sch Med, Dept Pediat, Atlanta, GA, Australia..
    Salit, R.
    Fred Hutchinson Canc Res Ctr, Seattle, WA USA..
    Gale, R. P.
    Imperial Coll London, Hematol Res Ctr, Div Expt Med, Dept Med, London, England..
    Martino, R.
    Hosp Santa Creu St Pau, Div Clin Hematol, Barcelona, Spain..
    Jaglowski, S.
    Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA..
    Bajel, A.
    Royal Melbourne Hosp City Campus, Melbourne, Australia..
    Savani, B.
    Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Dept Med, Nashville, TN USA..
    Frangoul, H.
    Vanderbilt Univ, Sch Med, Div Hematol Oncol, Dept Pediat, Nashville, TN USA..
    Lewis, I. D.
    Royal Adelaide Hosp, Haematol & Bone Marrow Transplant Unit, Adelaide, SA, Australia..
    Storek, J.
    Univ Calgary, Dept Med, Calgary, AB, Canada..
    Askar, M.
    Baylor Univ, Med Ctr, Dallas, TX USA..
    Kharfan-Dabaja, M. A.
    H Lee Mofitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA..
    Aljurf, M.
    King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia..
    Ringden, O.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden..
    Reshef, R.
    Columbia Univ, Med Ctr, Blood & Marrow Transplantat Program, Columbia Ctr Translat Immunol, New York, NY USA..
    Olsson, R. F.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden..
    Hashmi, S.
    Mayo Clin Rochester, Rochester, MN USA..
    Seo, S.
    Nat Canc Res Ctr, East Hosp, Kashiwa, Chiba, Japan..
    Spitzer, T. R.
    MacMillan, M. L.
    Univ Minnesota, Med Ctr, Minneapolis, MN USA..
    Lazaryan, A.
    Univ Minnesota, Med Ctr, Div Hematol Oncol, Dept Med, Minneapolis, MN USA..
    Spellman, S. R.
    Arora, M.
    Cutler, C. S.
    Dana Farber Canc Inst, Ctr Hematol Oncol, Dept Med Oncol, Boston, MA USA..
    GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes2017In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 52, no 3, p. 400-408Article in journal (Refereed)
    Abstract [en]

    Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we analyzed 1404 umbilical cord blood transplantation (UCBT) patients (single (>= 18 years) = 810, double (< 18 years) = 594) with acute leukemia to define the incidence of acute GvHD (aGvHD) and chronic GvHD (cGvHD), analyze clinical risk factors and investigate outcomes. After single UCBT, 100-day incidence of grade II-IV aGvHD was 39% (95% confidence interval (CI), 36-43%), grade III-IV aGvHD was 18% (95% CI, 15-20%) and 1-year cGvHD was 27% (95% CI, 24-30%). After double UCBT, 100-day incidence of grade II-IV aGvHD was 45% (95% CI, 41-49%), grade III-IV aGvHD was 22% (95% CI, 19-26%) and 1-year cGvHD was 26% (95% CI, 22-29%). For single UCBT, multivariate analysis showed that absence of antithymocyte globulin (ATG) was associated with aGvHD, whereas prior aGvHD was associated with cGvHD. For double UCBT, absence of ATG and myeloablative conditioning were associated with aGvHD, whereas prior aGvHD predicted for cGvHD. Grade III-IV aGvHD led to worse survival, whereas cGvHD had no significant effect on disease-free or overall survival. GvHD is prevalent after UCBT with severe aGvHD leading to higher mortality. Future research in UCBT should prioritize prevention of GvHD.

  • 76.
    Cheng, Yee Chung
    et al.
    Med Coll Wisconsin, Milwaukee, WI 53226 USA.
    Shi, Yushu
    Med Coll Wisconsin, Milwaukee, WI 53226 USA..
    Zhang, Mei-Jie
    Med Coll Wisconsin, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Milwaukee, WI 53226 USA..
    Brazauskas, Ruta
    Med Coll Wisconsin, Milwaukee, WI 53226 USA..
    Hemmer, Michael T.
    Med Coll Wisconsin, Milwaukee, WI 53226 USA..
    Bishop, Michael R.
    Univ Chicago Hosp, Chicago, IL 60637 USA..
    Nieto, Yago
    Univ Texas, Houston, TX 77030 USA..
    Stadtmauer, Edward
    Univ Penn, Philadelphia, PA 19104 USA..
    Ayash, Lois
    Karmanos Canc Inst, Detroit, MI USA.;Univ Minnesota, Minneapolis, MN 55455 USA..
    Gale, Robert Peter
    Imperial Coll London, London, England..
    Lazarus, Hillard
    Univ Hosp, Cleveland, OH USA..
    Holmberg, Leona
    Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA..
    Lill, Michael
    Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA..
    Olsson, R
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Stockholm, Sweden..
    Wirk, Baldeep Mona
    Seattle Canc Care Alliance, Seattle, WA USA..
    Arora, Mukta
    Univ Minnesota, Minneapolis, MN 55455 USA..
    Hari, Parameswaran
    Med Coll Wisconsin, Milwaukee, WI 53226 USA..
    Ueno, Naoto
    Univ Texas, Houston, TX 77030 USA..